



(51) International Patent Classification:

A61K 31/343 (2006.01)

(21) International Application Number:

PCT/US2014/043075

(22) International Filing Date:

19 June 2014 (19.06.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2013/000745 24 June 2013 (24.06.2013) CN

(71) Applicant (for all designated States except US): **MERCK SHARP & DOHME CORP.** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).(71) Applicant (for NZ, US only): **SOLL, Richard** [US/CN]; 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131 (CN).

(72) Inventors; and

(71) Applicants (for US only): **HE, Shuwen** [CN/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **LAI, Zhong** [CN/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **DAI, Xing** [CN/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **XIAO, Dong** [CN/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **LONDON, Clare** [GB/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **ZORN, Nicolas** [US/US]; 364 La Grande Ave., Fanwood, New Jersey 07023 (US). **NARGUND, Ravi** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **PALANI, Anandan** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **MCCOMAS, Casey**,

C. [US/US]; 470 Springview Lane, Phoenixville, Pennsylvania 19460 (US).

(72) Inventors; and


(71) Applicants (for NZ, US only): **LI, Peng** [CN/CN]; 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131 (CN). **PENG, Xuanjia** [CN/CN]; 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131 (CN).(74) Common Representative: **MERCK SHARP & DOHME CORP.**; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C



(57) Abstract: The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.(I)

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

TITLE OF THE APPLICATION

HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE
TREATMENT OF HEPATITIS C

5 FIELD OF THE INVENTION

The present disclosure relates to compounds that are useful as inhibitors of the hepatitis C virus (HCV) NS5B (non-structural protein 5B) polymerase, compositions comprising such compounds, the use of such compounds for treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection, methods for inhibiting the function of the
10 NS5B polymerase, and methods for inhibiting HCV viral replication and/or viral production.

BACKGROUND OF THE INVENTION

Hepatitis C virus (HCV) infection is a major health problem that leads to chronic liver disease, such as cirrhosis and hepatocellular carcinoma, in a substantial number of infected
15 individuals. Current treatments for HCV infection include immunotherapy with recombinant interferon- α alone or in combination with the nucleoside analog ribavirin.

Several virally-encoded enzymes are putative targets for therapeutic intervention, including a metalloprotease (NS2-3), a serine protease (NS3, amino acid residues 1-180), a helicase (NS3, full length), an NS3 protease cofactor (NS4A), a membrane protein (NS4B), a
20 zinc metalloprotein (NS5A) and an RNA-dependent RNA polymerase (NS5B).

One identified target for therapeutic intervention is HCV NS5B polymerase. Sven-Erik Behrens *et al.*, *Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus*, 15(1) EMBO J. 12-22 (1996). Antagonists of NS5B activity are inhibitors of HCV replication. Steven S. Carroll *et al.*, *Inhibition of Hepatitis C Virus RNA Replication by 2'-Modified Nucleoside Analogs*, 278(14) J. BIOL. CHEM. 11979-84 (2003).
25


There is a clear and long-felt need to develop effective therapeutics for treatment of HCV infection. Specifically, there is a need to develop compounds that inhibit HCV viral replication and that would be useful for treating HCV-infected patients.

30 SUMMARY OF THE INVENTION

The present disclosure relates to novel compounds of formula I and pharmaceutically acceptable salts thereof. These compounds are useful, either as compounds or

their pharmaceutically acceptable salts (when appropriate), in the inhibition of HCV (hepatitis C virus) NS5B (non-structural 5B) polymerase, the prevention or treatment of one or more of the symptoms of HCV infection, the inhibition of HCV viral replication and/or HCV viral production, and/or as pharmaceutical composition ingredients. As pharmaceutical composition ingredients, these compounds and their salts may be the primary active therapeutic agent, and, when appropriate, may be combined with other therapeutic agents including but not limited to other HCV antivirals, anti-infectives, immunomodulators, antibiotics or vaccines, as well as the present Standard of Care treatment options for HCV.

In one aspect, the present invention relates to a compound of formula I:



or a pharmaceutically acceptable salt thereof,
wherein:

X is a 5 or 6-membered saturated monocyclic ring with 1 or 2 heteroatom ring atoms independently selected from N and O;

A is fluorophenyl;

- B is
- a) hydrogen;
 - b) $-\text{C}(\text{O})\text{CH}=\text{C}(\text{CH}_3)_2$;
 - c) Ar;
 - d) $-\text{C}(\text{O})-\text{Ar}$;
 - e) $-\text{C}(\text{O})\text{CHR}^y-\text{Ar}$;
 - f) $-\text{C}(\text{O})\text{CH}(\text{NHR}^x)-\text{Ar}$;
 - g) $-\text{SO}_2(\text{CH}_2)_{0-2}-\text{Ar}$;
 - h) $-\text{SO}_2-\text{CH}=\text{CH}-\text{Ar}$;
 - i) $-\text{CO}-\text{Cyc}$;
 - j) $-\text{COCH}_2-\text{Cyc}$;
 - k) $-\text{SO}_2-\text{Cyc}$;

Ar is an aromatic ring system selected from:

(i) 5-6 membered monocyclic ring with 0, 1, or 2 heteroatom ring atoms independently selected from N or O, optionally substituted with 1 or 2 substituents independently selected from fluorophenyl, C₁-C₆ alkyl, and halo; and

(ii) 8-10 membered bicyclic rings with 1, 2 or 3 heteroatom ring atoms selected from N, O and S, optionally substituted with 1, 2 or 3 substituents independently selected from C₁-C₆ alkyl, C₁-C₆ alkoxy, halo, CF₃, cyano, oxo, -NH₂, and cyclopropylmethyl;

Cyc is C₃-C₆ cycloalkyl optionally substituted with fluorophenyl or pyridine; or

3-oxabicyclo[3.1.0]hexane;

D is H or NR³SO₂R⁴;

R², R³, and R⁴ are independently C₁-C₆ alkyl;

R^a is hydrogen or C₁-C₆ alkyl;

R^x is hydrogen or C(O)OC(CH₃)₃; and

R^y is hydrogen, morpholinyl or Ar.


The present invention also includes pharmaceutical compositions containing a compound of the present invention and methods of preparing such pharmaceutical compositions. The present invention further includes methods of treating or reducing the likelihood or severity of HCV infection, methods for inhibiting the activity of the NS5B polymerase, and methods for inhibiting HCV viral replication and/or viral production.

Other embodiments, aspects and features of the present invention are either further described in or will be apparent from the ensuing description, examples and appended claims.

DETAILED DESCRIPTION OF THE INVENTION

The present invention includes compounds of formula I above, and pharmaceutically acceptable salts thereof. The compounds of formula I are HCV NS5B polymerase inhibitors.

In an aspect of the invention, X is




In a first embodiment of the invention, R^2 , R^3 and R^4 are methyl, and the other groups are as provided in the general formula above or as in the first aspect.

5 In a second embodiment of the invention, D is $N(CH_3)SO_2CH_3$, and the other groups are as provided in the general formula above, as in the first aspect, or as in the first embodiment.

In a third embodiment of the invention, each halo is F, and the other groups are as provided in the general formula above, as in the first aspect or as in the first or second
10 embodiments.

In a fourth embodiment of the invention, the compound of the invention has the formula




or a pharmaceutically acceptable salt thereof, and the groups are as provided in the general
15 formula above, as in the first aspect or as in the first through third embodiments.

In a fifth embodiment of the invention, X is , and the other groups are as provided in the general formula above, or as in the first through fourth embodiments.

In a sixth embodiment of the invention, B is Ar, $-C(O)-Ar$, or $-SO_2-Ar$; wherein Ar is a 9-membered bicyclic ring with 1, 2, or 3 heteroatom ring atoms selected from N, O and S, optionally substituted with 1, 2 or 3 substituents independently
20 selected from C_1-C_6 alkyl, C_1-C_6 alkoxy, F, CF_3 , and cyano, and the other groups are as provided

in the general formula above, as in the first aspect or as in the first through fifth embodiments.

In an aspect of this sixth embodiment, Ar is



wherein each R^p is independently selected from hydrogen, methyl, methoxy, F, CF₃, or cyano, and R^q is hydrogen, methyl or ethyl, and the other groups are as provided in the general formula above, as in the first aspect or as in the first through fifth embodiments.

10 In a seventh embodiment of the invention, B is -SO₂-Ar, -SO₂CH₂-Ar, -SO₂CH₂CH₂-Ar, -C(O)-Ar; or -C(O)CH₂-Ar; wherein Ar is phenyl, methylphenyl, fluorophenyl, difluorophenyl, pyridine, or fluoropyridine, and the other groups are as provided in the general formula above, as in the first aspect or as in the first through sixth embodiments.

In certain aspects of the invention, a fluorophenyl is para-fluorophenyl.

15 In another embodiment of the invention, the compound of the invention is selected from the exemplary species depicted in Examples 1-144 shown below, and pharmaceutically acceptable salts thereof.

In another embodiment of the invention, the compound of the invention is selected from the exemplary species depicted in Examples 2, 4, 7, 11, 14, 25, 35, 37, 38 and 59
20 shown below, and pharmaceutically acceptable salts thereof.

Other embodiments of the present invention include the following:

(a) A pharmaceutical composition comprising an effective amount of a compound of formula **I** and a pharmaceutically acceptable carrier.

(b) The pharmaceutical composition of (a), further comprising a second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents.

(c) The pharmaceutical composition of (b), wherein the HCV antiviral agent is an antiviral selected from the group consisting of direct inhibitors of HCV, including but not limited to NS3 and NS3/4A protease inhibitors, NS5A inhibitors and HCV NS5B polymerase inhibitors.

(d) A pharmaceutical combination that is (i) a compound of formula **I** and (ii) a second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents; wherein the compound of formula **I** and the second therapeutic agent are each employed in an amount that renders the combination effective for inhibiting HCV NS5B activity, or for inhibiting HCV viral replication, or for treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection.

(e) The combination of (d), wherein the HCV antiviral agents are one or more antiviral agents selected from the group consisting of direct inhibitors of HCV, including but not limited to NS3 and NS3/4A protease inhibitors, NS5A inhibitors and HCV NS5B polymerase inhibitors.

(f) A use of a compound of formula **I** in the preparation of a medicament for inhibiting HCV NS5B activity in a subject in need thereof.

(g) A use of a compound of formula **I** in the preparation of a medicament for preventing and/or treating infection by HCV in a subject in need thereof.

(h) A method of treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection in a subject in need thereof, which comprises administering to the subject an effective amount of a compound of formula **I**.

(i) The method of (h), wherein the compound of formula **I** is administered in combination with an effective amount of at least one second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents.

(j) The method of (i), wherein the HCV antiviral agent is an antiviral selected from the group consisting of direct inhibitors of HCV, including but not limited to NS3 and NS3/4A protease inhibitors, NS5A inhibitors and HCV NS5B polymerase inhibitors.

(k) A method of inhibiting HCV viral replication and/or HCV viral
5 production in a cell-based system, which comprises administering to the subject an effective amount of a compound of formula I in combination with an effective amount of at least one second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents.

(l) The method of (k), wherein the HCV antiviral agent is an antiviral
10 selected from the group consisting of direct inhibitors of HCV, including but not limited to NS3 and NS3/4A protease inhibitors, NS5A inhibitors and HCV NS5B polymerase inhibitors.

(m) A method of inhibiting HCV NS5B activity in a subject in need thereof, which comprises administering to the subject the pharmaceutical composition of (a), (b), or (c) or the combination of (d) or (e).

(n) A method of treating HCV infection and/or reducing the likelihood or
15 severity of symptoms of HCV infection in a subject in need thereof, which comprises administering to the subject the pharmaceutical composition of (a), (b), or (c) or the combination of (d) or (e).

In the embodiments of the compounds and salts provided above, it is to be
20 understood that each embodiment may be combined with one or more other embodiments, to the extent that such a combination provides a stable compound or salt and is consistent with the description of the embodiments. It is further to be understood that the embodiments of compositions and methods provided as (a) through (n) above are understood to include all embodiments of the compounds and/or salts, including such embodiments as result from
25 combinations of embodiments.

Additional embodiments of the invention include the pharmaceutical
compositions, combinations, uses and methods set forth in (a) through (n) above, wherein the
compound of the present invention employed therein is a compound of one of the embodiments,
aspects, classes, sub-classes, or features of the compounds described above. In all of these
30 embodiments, the compound may optionally be used in the form of a pharmaceutically acceptable salt or hydrate as appropriate.

The present invention also includes a compound of the present invention for use (i) in, (ii) as a medicament for, or (iii) in the preparation of a medicament for: (a) inhibiting HCV NS5B activity, or (b) inhibiting HCV viral replication, or (c) treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection, or (d) use in medicine. In these uses, the compounds of the present invention can optionally be employed in combination with one or more second therapeutic agents selected from HCV antiviral agents, anti-infective agents, and immunomodulators.

Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name and an ambiguity exists between the structure and the name, the structure is understood to predominate.

As used herein, the term "administration" and variants thereof (*e.g.*, "administering" a compound) in reference to a compound of the invention mean providing the compound to the individual in need of treatment. When a compound of the invention is provided in combination with one or more other active agents (*e.g.*, antiviral agents useful for treating HCV infection), "administration" and its variants are each understood to include concurrent and sequential provision of the compound or salt and other agents.

As used herein, the term "alkoxy" refers to an "alkyl-O-" group. Alkoxy groups may be substituted as indicated.

The term "alkyl" refers to an aliphatic hydrocarbon group having one of its hydrogen atoms replaced with a bond. An alkyl group may be straight or branched and contain from about 1 to about 20 carbon atoms. In one embodiment, an alkyl group contains from about 1 to about 12 carbon atoms. In different embodiments, an alkyl group contains from 1 to 6 carbon atoms (C₁-C₆ alkyl) or from about 1 to about 3 carbon atoms (C₁-C₃ alkyl). Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, neopentyl, isopentyl, n-hexyl, isohexyl and neohexyl. In one embodiment, an alkyl group is linear. In another embodiment, an alkyl group is branched.

The term "aryl" (or "aromatic ring system") refers to aromatic mono- and polycarbocyclic ring systems wherein the individual carbocyclic rings in the polyring systems are fused or attached to each other via a single bond. As used herein, the term aryl includes aromatic mono- and polycarbocyclic ring systems that include from 0 to 4 heteroatoms (non-carbon atoms) that are independently chosen from N, O and S. Aromatic ring systems also includes ring


systems where an aromatic ring is fused to a saturated ring. Suitable aryl groups include phenyl, naphthyl, biphenylenyl, pyridinyl, pyrimidinyl and pyrrolyl, as well as those discussed below. Aryl ring systems may include, where appropriate, an indication of the variable to which a particular ring atom is attached. Unless otherwise indicated, substituents to the aryl ring systems
5 can be attached to any ring atom, provided that such attachment results in formation of a stable ring system.

The term "composition" is intended to encompass a product comprising the specified ingredients, as well as any product which results from combining the specified ingredients.

10 The term "compound" is intended to encompass chemical agents described by generic formula I in all forms. Such chemical agents can be present in different forms such as hydrates and solvates.

The term "cycloalkyl," as used herein, refers to a non-aromatic mono- or multicyclic ring system comprising from about 3 to about 10 ring carbon atoms. In one
15 embodiment, a cycloalkyl contains from about 5 to about 10 ring carbon atoms. In another embodiment, a cycloalkyl contains from about 3 to about 7 ring atoms. In another embodiment, a cycloalkyl contains from about 5 to about 7 ring atoms. In another embodiment, a cycloalkyl contains from about 5 to about 6 ring atoms. The term "cycloalkyl" also encompasses a cycloalkyl group, as defined above, which is fused to an aryl (*e.g.*, benzene) or heteroaryl ring.

20 Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Non-limiting examples of multicyclic cycloalkyls include 1-decalinyl, norbornyl, bicyclo[3.1.0]hexyl and adamantyl. The term "3 to 7-membered cycloalkyl" refers to a cycloalkyl group having from 3 to 7 ring carbon atoms. A ring carbon atom of a cycloalkyl group may be functionalized as a carbonyl group. An illustrative example
25 of such a cycloalkyl group (also referred to herein as a "cycloalkanoyl" group) includes, but is not limited to, cyclobutanoyl:



The term "effective amount" as used herein means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue,

system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. In one embodiment, the effective amount is a "therapeutically effective amount" for the alleviation of one or more symptoms of the disease or condition being treated. In another embodiment, the effective amount is a "prophylactically effective amount" for reduction of the severity or likelihood of one or more symptoms of the disease or condition. In another embodiment, the effective amount is a "therapeutically effective amount" for inhibition of HCV viral replication and/or HCV viral production. The term also includes herein the amount of active compound sufficient to inhibit HCV NS5B activity and thereby elicit the response being sought (*i.e.*, an "inhibition effective amount"). When the active compound (*i.e.*, active ingredient) is administered as the salt, references to the amount of active ingredient are to the free acid or free base form of the compound.

The term "haloalkyl," as used herein, refers to an alkyl group as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with a halogen. In one embodiment, a haloalkyl group has from 1 to 6 carbon atoms. In another embodiment, a haloalkyl group is substituted with from 1 to 3 F atoms. Non-limiting examples of haloalkyl groups include $-\text{CH}_2\text{F}$, $-\text{CHF}_2$, $-\text{CF}_3$, $-\text{CH}_2\text{Cl}$ and $-\text{CCl}_3$. The term " $\text{C}_1\text{-C}_6$ haloalkyl" refers to a haloalkyl group having from 1 to 6 carbon atoms.

The term "halogen" (or "halo") refers to atoms of fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo).

The term "heteroaryl," as used herein, refers to an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, wherein from 1 to 4 of the ring atoms is independently O, N or S and the remaining ring atoms are carbon atoms. In one embodiment, a heteroaryl group has 5 to 10 ring atoms. In another embodiment, a heteroaryl group is monocyclic and has 5 or 6 ring atoms. In another embodiment, a heteroaryl group is bicyclic and has 9 or 10 ring atoms. A heteroaryl group is joined via a ring carbon atom, and any nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide. The term "heteroaryl" also encompasses a heteroaryl group, as defined above, which is fused to a benzene ring. The term "heteroaryl" also encompasses any fused polycyclic ring system containing at least one ring heteroatom selected from N, O and S, wherein at least one ring of the fused polycyclic ring system is aromatic. For example, the term "9 to 10-membered bicyclic heteroaryl" encompasses a non-aromatic 5 membered heterocyclic ring that is fused to a benzene or pyridyl ring. Non-limiting examples of heteroaryls include pyridyl, pyrazinyl, furanyl,

thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalanyl, phthalazinyl, oxindolyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinoliny, imidazolyl, benzimidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinoliny, benzoazaindolyl, 1,2,4-triazinyl, benzothiazolyl and the like, and all isomeric forms thereof. The term "heteroaryl" also refers to partially saturated heteroaryl moieties such as, for example, tetrahydroisoquinolyl, tetrahydroquinolyl and the like. In one embodiment, a heteroaryl group is a 5-membered heteroaryl. In another embodiment, a heteroaryl group is a 6-membered heteroaryl. In another embodiment, a heteroaryl group comprises a 5- to 6-membered heteroaryl group fused to a benzene ring.

The term "hydroxyalkyl," as used herein, refers to an alkyl group as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with an -OH group. In one embodiment, a hydroxyalkyl group has from 1 to 6 carbon atoms. Non-limiting examples of hydroxyalkyl groups include -CH₂OH, -CH₂CH₂OH, -CH₂CH₂CH₂OH and -CH₂CH(OH)CH₃. The term "C₁-C₆ hydroxyalkyl" refers to a hydroxyalkyl group having from 1 to 6 carbon atoms.

As used herein, the term "oxo" or "=O" forms a carbonyl moiety with the carbon atom to which it is attached.

By "pharmaceutically acceptable" is meant that the ingredients of the pharmaceutical composition must be compatible with each other and not deleterious to the recipient thereof.

The term "preventing," as used herein with respect to an HCV viral infection or HCV-virus related disorder, refers to reducing the likelihood of HCV infection.

The term "subject" (alternatively referred to herein as "patient"), as used herein, refers to an animal, preferably a mammal, most preferably a human.

The term "substituted" means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Unless expressly stated to the contrary, substitution by a named substituent is permitted on any atom provided such substitution is chemically allowed and results in a stable compound. Combinations of substituents and/or variables are permissible only if such

combinations result in stable compounds. A "stable" compound is a compound that can be prepared and isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (*e.g.*, therapeutic or prophylactic administration to a subject).

5 In the compounds of formula I, the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of formula I. For example, different isotopic
10 forms of hydrogen (H) include protium (^1H) and deuterium (^2H or D). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing *in vivo* half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched compounds within formula I can be prepared without undue
15 experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.

Unless expressly stated to the contrary, all ranges cited herein are inclusive. For example, a heteroaryl ring described as containing from "1 to 3 heteroatoms" means the ring can
20 contain 1, 2, or 3 heteroatoms. It is also to be understood that any range cited herein includes within its scope all of the sub-ranges within that range. The oxidized forms of the heteroatoms N and S are also included within the scope of the present invention.

When any variable (for example, R^1 or R^3) occurs more than one time in any constituent or in formula I or in any other formula depicting and describing compounds of the
25 invention, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

Certain of the compounds of the present invention can have asymmetric centers and can occur as mixtures of stereoisomers, or as individual diastereomers, or enantiomers. All
30 isomeric forms of these compounds, whether isolated or in mixtures, are within the scope of the present invention.

Certain of the compounds of the present invention can exist as tautomers. For the purposes of the present invention a reference to a compound of formula I is a reference to the compound *per se*, or to any one of its tautomers *per se*, or to mixtures of two or more tautomers.

The compounds of the present inventions are useful in the inhibition of HCV replication (*e.g.*, HCV NS5B activity), the treatment of HCV infection and/or reduction of the likelihood or severity of symptoms of HCV infection. For example, the compounds of this invention are useful in treating infection by HCV after suspected past exposure to HCV by such means as blood transfusion, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.

The compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds. For example, the compounds of this invention are useful for identifying resistant HCV replicon cell lines harboring mutations within NS5B, which are excellent screening tools for more powerful antiviral compounds. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other antivirals to the HCV replicase.

The compounds of the present invention may be administered in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" refers to a salt that possesses the effectiveness of the parent compound and that is not biologically or otherwise undesirable (*e.g.*, is neither toxic nor otherwise deleterious to the recipient thereof). Suitable salts include acid addition salts that may, for example, be formed by mixing a solution of the compound of the present invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid. Many of the compounds of the invention carry an acidic moiety, in which case suitable pharmaceutically acceptable salts thereof can include alkali metal salts (*e.g.*, sodium or potassium salts), alkaline earth metal salts (*e.g.*, calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts. Also, in the case of an acid (-COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound.

Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates ("mesylates"), naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates,

succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl *et al*, Camille G. (eds.) *Handbook of Pharmaceutical Salts. Properties, Selection and Use*. (2002) Zurich: Wiley-VCH; S. Berge *et al*, *Journal of Pharmaceutical Sciences* (1977) 66(1) 1-19; P. Gould, *International J. of Pharmaceutics* (1986) 33 201-217; Anderson *et al*, *The Practice of Medicinal Chemistry* (1996), Academic Press, New York; and in *The Orange Book* (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto.

Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamine, t-butyl amine, choline, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (*e.g.*, methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (*e.g.*, dimethyl, diethyl, and dibutyl sulfates), long chain halides (*e.g.*, decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (*e.g.*, benzyl and phenethyl bromides), and others.

For the purposes of inhibiting HCV NS5B polymerase, treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection and inhibiting HCV viral replication and/or HCV viral production, the compounds of the present invention, optionally in the form of a salt, can be administered by any means that produces contact of the active agent with the agent's site of action. They can be administered by one or more conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but typically are administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. The compounds of the invention can, for example, be administered by one or more of the following: orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques), by inhalation (such as in a spray form), or rectally, in the form of a unit dosage of a pharmaceutical composition containing an effective amount of the compound and conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles. Liquid preparations suitable for oral administration (*e.g.*, suspensions, syrups, elixirs and the like) can be prepared


according to techniques known in the art and can employ any of the usual media such as water, glycols, oils, alcohols and the like. Solid preparations suitable for oral administration (*e.g.*, powders, pills, capsules and tablets) can be prepared according to techniques known in the art and can employ such solid excipients as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like. Parenteral compositions can be prepared according to techniques known in the art and typically employ sterile water as a carrier and optionally other ingredients, such as solubility aids. Injectable solutions can be prepared according to methods known in the art wherein the carrier comprises a saline solution, a glucose solution or a solution containing a mixture of saline and glucose. Further description of methods suitable for use in preparing pharmaceutical compositions of the present invention and of ingredients suitable for use in said compositions is provided in Remington's Pharmaceutical Sciences, 18th edition (ed. A. R. Gennaro, Mack Publishing Co., 1990).

The compounds of this invention can be administered orally in a dosage range of 0.001 to 1000 mg/kg of mammal (*e.g.*, human) body weight per day in a single dose or in divided doses. One dosage range is 0.01 to 500 mg/kg body weight per day orally in a single dose or in divided doses. Another dosage range is 0.1 to 100 mg/kg body weight per day orally in single or divided doses. For oral administration, the compositions can be provided in the form of tablets or capsules containing 1.0 to 500 mg of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, HCV viral genotype, viral resistance, and the host undergoing therapy.

As noted above, the present invention also relates to a method of inhibiting HCV NS5B activity, inhibiting HCV viral replication and/or HCV viral production, treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection with a compound of the present invention in combination with one or more therapeutic agents and a pharmaceutical composition comprising a compound of the present invention and one or more therapeutic agents selected from the group consisting of a HCV antiviral agent, an immunomodulator, and an anti-infective agent. Such agents are described in detail below.

HCV polymerase inhibitors useful in the present compositions and methods include, but are not limited to, VP-19744 (Wyeth/ViroPharma), PSI-7851 (Pharmasset), RG7128 (Roche/Pharmasset), PSI-7977 (Pharmasset), PSI-938 (Pharmasset), PSI-879 (Pharmasset), PSI-661 (Pharmasset), PF-868554/filibuvir (Pfizer), VCH-759/VX-759 (ViroChem Pharma/Vertex),
 5 HCV-371 (Wyeth/ViroPharma), HCV-796 (Wyeth/ViroPharma), IDX-184 (Idenix), IDX-375 (Idenix), NM-283 (Idenix/Novartis), GL-60667 (Genelabs), JTK-109 (Japan Tobacco), PSI-6130 (Pharmasset), R1479 (Roche), R-1626 (Roche), R-7128 (Roche), MK-0608 (Isis/Merck), INX-8014 (Inhibitex), INX-8018 (Inhibitex), INX-189 (Inhibitex), GS 9190 (Gilead), A-848837 (Abbott), ABT-333 (Abbott), ABT-072 (Abbott), A-837093 (Abbott), BI-207127 (Boehringer-
 10 Ingelheim), BILB-1941 (Boehringer-Ingelheim), MK-3281 (Merck), VCH-222/VX-222 (ViroChem/Vertex), VCH-916 (ViroChem), VCH-716(ViroChem), GSK-71185 (Glaxo SmithKline), ANA598 (Anadys), GSK-625433 (Glaxo SmithKline), XTL-2125 (XTL Biopharmaceuticals), and those disclosed in Ni *et al.*, *Current Opinion in Drug Discovery and Development*, 7(4):446 (2004); Tan *et al.*, *Nature Reviews*, 1:867 (2002); and Beaulieu *et al.*,
 15 *Current Opinion in Investigational Drugs*, 5:838 (2004).

Other HCV polymerase inhibitors useful in the present compositions and methods include, but are not limited to, those disclosed in International Publication Nos. WO 08/082484, WO 08/082488, WO 08/083351, WO 08/136815, WO 09/032116, WO 09/032123, WO
 20 09/032124 and WO 09/032125; and the following compounds:




and pharmaceutically acceptable salts thereof.


Interferons useful in the present compositions and methods include, but are not limited to, interferon alfa-2a, interferon alfa-2b, interferon alfacon-1 and petroleum etherG-
 25 interferon alpha conjugates. "PEG-interferon alpha conjugates" are interferon alpha molecules covalently attached to a petroleum etherG molecule. Illustrative petroleum etherG-interferon alpha conjugates include interferon alpha-2a (RoferonTM, Hoffman La-Roche, Nutley, New Jersey) in the form of pegylated interferon alpha-2a (*e.g.*, as sold under the trade name


PegasysTM), interferon alpha-2b (IntronTM, from Schering-Plough Corporation) in the form of pegylated interferon alpha-2b (*e.g.*, as sold under the trade name petroleum etherG-IntronTM from Schering-Plough Corporation), interferon alpha-2b-XL (*e.g.*, as sold under the trade name petroleum etherG-IntronTM), interferon alpha-2c (Berofer AlphaTM, Boehringer Ingelheim, 5 Ingelheim, Germany), petroleum etherG-interferon lambda (Bristol-Myers Squibb and ZymoGenetics), interferon alfa-2b alpha fusion polypeptides, interferon fused with the human blood protein albumin (AlbuferonTM, Human Genome Sciences), Omega Interferon (Intarcia), Locteron controlled release interferon (Biolex/OctoPlus), Biomed-510 (omega interferon), Peg-IL-29 (ZymoGenetics), Locteron CR (Octopus), R-7025 (Roche), IFN- α -2b-XL (Flamel 10 Technologies), belerofon (Nautilus) and consensus interferon as defined by determination of a consensus sequence of naturally occurring interferon alphas (InfergenTM, Amgen, Thousand Oaks, California).


Examples of viral protease inhibitors useful in the present compositions and methods include, but are not limited to, an HCV protease inhibitor. Examples of HCV protease 15 inhibitors useful in the present compositions and methods include, but are not limited to, VX-950 (Telaprevir, Vertex), VX-500 (Vertex), VX-813 (Vertex), VBY-376 (Virobay), BI-201335 (Boehringer Ingelheim), TMC-435 (Medivir/Tibotec), ABT-450 (Abbott/Enanta), TMC-435350 (Medivir), RG7227 (Danoprevir, InterMune/Roche), EA-058 (Abbott/Enanta), EA-063 (Abbott/Enanta), GS-9256 (Gilead), IDX-320 (Idenix), ACH-1625 (Achillion), ACH-2684 20 (Achillion), GS-9132 (Gilead/Achillion), ACH-1095 (Gilead/Achillion), IDX-136 (Idenix), IDX-316 (Idenix), ITMN-8356 (InterMune), ITMN-8347 (InterMune), ITMN-8096 (InterMune), ITMN-7587 (InterMune), BMS-650032 (Bristol-Myers Squibb), VX-985 (Vertex) and PHX1766 (Phenomix).

Further examples of HCV protease inhibitors useful in the present compositions 25 and methods include, but are not limited to, the following compounds:











and pharmaceutically acceptable salts thereof.

Viral replication inhibitors useful in the present compositions and methods include, but are not limited to, HCV replicase inhibitors, IRES inhibitors, NS4A inhibitors, NS3 helicase inhibitors, NS5A inhibitors, NS5B inhibitors, ribavirin, AZD-2836 (Astra Zeneca), viramidine, A-831 (Arrow Therapeutics), EDP-239 (Enanta), ACH-2928 (Achillion), GS-5885 (Gilead); an antisense agent or a therapeutic vaccine.

HCV NS5A inhibitors useful in the present compositions and methods include, but are not limited to, ACH-2928 (Achilon), A-832 (Arrow Therapeutics), AZD-7295 (Astra Zeneca/Arrow), GS-5885 (Gilead), PPI-461 (Presidio), PPI-1301 (Presidio), BMS-824383 (Bristol-Myers Squibb) and BMS-790052 (Bristol-Myers Squibb). Additional HCV NS5A inhibitors useful as second additional therapeutic agents in the present compositions and methods include, but are not limited to those disclosed in International Publication No. WO 2010/111483 and the following compounds:





and

and pharmaceutically acceptable salts thereof.

HCV replicase inhibitors useful in the present compositions and methods include,

10 but are not limited to, those disclosed in U.S. Patent Publication No. US20090081636.

When administering a combination therapy of the invention to a patient, therapeutic agents in the combination, or a pharmaceutical composition or compositions comprising therapeutic agents, may be administered in any order such as, for example, sequentially, concurrently, together, simultaneously and the like. The amounts of the various
5 actives in such combination therapy may be different amounts (different dosage amounts) or same amounts (same dosage amounts). A compound of the invention and an additional therapeutic agent may be present in fixed amounts (dosage amounts) in a single dosage unit (*e.g.*, a capsule, a tablet and the like).

The HCV NS5B inhibitory activity of the present compounds may be tested using
10 assays known in the art. The HCV NS5B polymerase inhibitors described herein have activities in a genotype 1b replicon assay as described in the Examples. The assay is performed by incubating a replicon harboring cell-line in the presence of inhibitor for a set period of time and measuring the effect of the inhibitor on HCV replicon replication either directly by quantifying replicon RNA level, or indirectly by measuring enzymatic activity of a co-encoded reporter
15 enzyme such as luciferase or β -lactamase. By performing a series of such measurements at different inhibitor concentrations, the effective inhibitory concentration of the inhibitor (EC_{50} or EC_{90}) is determined. See Jan M. Vrolijk *et al.*, *A replicons-based bioassay for the measurement of interferons in patients with chronic hepatitis C*, 110 J. VIROLOGICAL METHODS 201 (2003). Such assays may also be run in an automated format for high through-put screening. See Paul
20 Zuck *et al.*, *A cell-based β -lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication*, 334 ANALYTICAL BIOCHEMISTRY 344 (2004).

The present invention also includes processes for making compounds of formula I. The compounds of the present invention can be readily prepared according to the following reaction schemes and examples, or modifications thereof, using readily available
25 starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art, but are not mentioned in greater detail. Furthermore, other methods for preparing compounds of the invention will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. Unless otherwise indicated, all variables
30 are as defined above. The following reaction schemes and examples serve only to illustrate the invention and its practice.

General Schemes


The Compounds of Formula (I) may be prepared from known or readily prepared starting materials, following methods known to one skilled in the art of organic synthesis.

Methods useful for making the Compounds of Formula (I) are set forth in the Examples below and generalized in Schemes 1-2 below. Alternative synthetic pathways and analogous structures will be apparent to those skilled in the art of organic synthesis. All stereoisomers and tautomeric forms of the compounds are contemplated.

Some commercially available starting materials and intermediates used for the synthesis of the Compounds of Formula (I) are available. These starting materials and intermediates are available from commercial suppliers such as Sigma-Aldrich (St. Louis, MO) and Acros Organics Co. (Fair Lawn, NJ). Such starting materials and intermediates compounds are used as received.


Scheme 1 shows methods useful for making a key intermediate (Intermediate 1) and its two individual enantiomers. Other intermediates with structures similar to Intermediate 1 were prepared as described in the experimental section.

Scheme 1



Scheme 2 shows methods useful for converting Intermediate 1 to amides, sulfonamide, or N-aryl compounds. In some cases, Intermediate 1 was used as an individual enantiomer (R or S); in other cases, Intermediate 1 was used as a racemate. In the latter case, the final compounds were separated into single compounds by chiral SFC.

Scheme 2

List of Abbreviations

a.q.	Aqueous
Boc	t-butyloxycarbonyl
Boc ₂ O	Di-tert-butyl-dicarbonate
B(O ⁱ Pr) ₃	Triisopropyl borate
(Bpin) ₂	Bis(pinacolato)diboron
n-BuLi	n-butyllithium
CDCl ₃	Trichloro(² H)methane or deuterio-trichloromethane
CO ₂	Carbon dioxide
DCM, CH ₂ Cl ₂	Dichloromethane
DEA	Diethanolamine
DIEA	N,N-Diisopropylethylamine
DMAP	4-dimethylaminopyridine
DMF	Dimethylformamide
DMSO	Dimethylsulfoxide
EDCI	N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide (also EDC)
Et	Ethyl
Et ₃ N	Triethylamine
EtOAc, EA	Ethyl acetate
EtOH, CH ₃ CH ₂ OH	Ethanol

HATU	(Dimethylamino)-N,N-dimethyl(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yloxy)methaniminium hexafluorophosphate
HCHO	Formaldehyde
HCl	Hydrochloric acid
H ₂	Hydrogen gas or atmosphere
HCOOH	Formic acid
H ₂ O	Water
H ₂ SO ₄	Sulfuric acid
HOAc, CH ₃ COOH	Acetic acid
HOBT, HOBt	1-Hydroxy benzotriazole
¹ H-NMR	Proton Nuclear Magnetic Resonance
HPLC	High Performance Liquid Chromatography
ISCO	In situ chemical oxidation
K ₂ CO ₃	Potassium carbonate
KOAc	Potassium acetate
K ₃ PO ₄	Potassium Phosphate
LDA	Lithium diisopropylamide
LiHMDS	Lithium hexamethyldisilazide
LiOH	Lithium hydroxide
MeCN, CH ₃ CN	Acetonitrile
MeI, CH ₃ I	Methyl iodide
MeOD	Methan(² H)ol
MeOH, CH ₃ OH	Methanol
MS	Mass spectroscopy
Ms	Methanesulfonyl (or mesyl) group
MsCl	Methanesulfonyl chloride
N ₂	Nitrogen gas or atmosphere
NaBH(OAc) ₃	Sodium triacetoxymethylborohydride
NaHCO ₃	Sodium bicarbonate
Na ₂ SO ₄	Sodium sulfate (anhydrous)
NCS	N-Chlorosuccinimide
NH ₄ Cl	Ammonium chloride


NMO	N-Methylmorpholine-N-Oxide
OsO ₄	Osmium tetroxide
PCC	Pyridinium Chlorochromate
Pd	Palladium
Pd ₂ (dba) ₃	Tris(dibenzylideneacetone)dipalladium(0)
Pd(dppf)Cl ₂	1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride
Pd(dtbpf)Cl ₂	1,1'-bis(di- <i>tert</i> -butylphosphino)ferrocene-dichloropalladium(II)
Pd(PPh ₃) ₄	Tetrakis(triphenylphosphine)palladium(0)
PE	Petroleum ether
Ph	Phenyl
Pt	Platinum
PtO ₂	Platinum (IV) oxide
PTSA	p-Toluenesulfonic acid
RT	Room temperature, approximately 25°C
sat	saturated
SFC	Supercritical fluid chromatography
SO ₂	Sulfur dioxide
SOCl ₂	Thionyl chloride
T ₃ P	Propylphosphonic Anhydride
TCDI	N,N'-Thiocarbonyldiimidazole
TEA	Triethylamine
TF ₂ NPh	N-phenyltrifluoromethanesulphonimide
TFA	Trifluoroacetic acid
THF	Tetrahydrofuran
TsOH	p-Toluenesulfonic acid
TLC	Thin layer chromatography

EXAMPLES


In the examples below, some enantiomer pairs are identified by consecutive example numbers without identifying which enantiomer corresponds to which example number.

- 5 The example numbers correspond to a specific peak number which was tested for activity.

Example 1: 5-(5-(4-fluorobenzo[d]oxazol-2-yl)-1-methylpiperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido) benzofuran-3-carboxamide



Step 1 - Synthesis of methyl 5-bromonicotinate




5

To cooled methanol (20 mL, 0°C) was added dropwise concentrated H₂SO₄ (2 mL). To the resulting clear solution was added 5-bromonicotinic acid (2 g, 10 mmol) and the mixture was refluxed for 3 h. After being cooled to room temperature, the solvent was evaporated and the residue was partitioned between EtOAc and water. The organic layer was washed with saturated NaHCO₃ (a.q.), dried over Na₂SO₄ and concentrated to give methyl 5-bromonicotinate (1.5 g, yield: 71%). ¹H-NMR (CDCl₃, 400 MHz) δ 9.10 (d, *J* = 1.6 Hz, 1H), 8.81 (d, *J* = 2.4 Hz, 1H), 8.41 (t, *J* = 2.4 Hz, 1H), 3.94 (s, 3H). MS (M+H)⁺: 216 / 218.

10

Step 2 - Synthesis of methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate




15

To a solution of methyl 5-bromonicotinate (1 g, 4.6 mmol), KOAc (920 mg, 9.2 mmol) and (Bpin)₂ (1.7 g, 6.9 mmol) in DMF (10 mL) was added Pd(dppf)Cl₂ under N₂, and the resulting reaction mixture was stirred for 4 h at 80°C. After the reaction mixture was concentrated, the residue was dissolved in DCM, then filtered, evaporated and the residue was purified by flash chromatography (PE / EtOAc = 4 / 1) to give the product of methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate (800 mg, yield: 66%). ¹H-NMR (CDCl₃, 400 MHz) δ 9.21 (d, *J* = 2.4 Hz, 1H), 9.03 (d, *J* = 2.0 Hz, 1H), 8.61 (t, *J* = 2.0 Hz, 1H), 3.90 (s, 3H), 1.31 (s, 12H). MS (M+H)⁺: 264.


20

Step 3 - Synthesis of methyl 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)nicotinate



To a solution of methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate (1.1 g, 2.4 mmol), 5-bromo-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (763 mg, 2.9 mmol) (prepared according to International Patent Application Publication No. WO 2011106992) and $K_3PO_4 \cdot 3H_2O$ (1.3 g, 4.8 mmol) in DMF (20 mL) was added $Pd(dppf)Cl_2$ under N_2 , and the resulting reaction mixture was stirred for 3 h at 90°C. After the reaction mixture was concentrated, the residue was dissolved in DCM, then filtered, evaporated and the residue was purified by column chromatography (PE / EtOAc = 4 / 1 to 1 / 1) to give the product of methyl 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)nicotinate (1 g, yield: 83%). ^1H -NMR ($CDCl_3$, 400 MHz) δ 7.17 (d, J = 1.2 Hz, 1H), 8.00 (d, J = 1.6 Hz, 1H), 8.40 (s, 1H), 7.83~7.87 (m, 3H), 7.59 (s, 1H), 7.16 (t, J = 8.4 Hz, 2H), 5.76 (d, J = 4.0 Hz, 1H), 3.92 (s, 3H), 3.15 (s, 3H), 2.92 (d, J = 4.8 Hz, 3H), 2.69 (s, 3H). MS ($M+H$)⁺: 512.


Step 4 - Synthesis of methyl 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)piperidine-3-carboxylate



To a solution of methyl 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)nicotinate (650 mg, 1.27 mmol) in MeOH : CH_3COOH = 4 : 1 (100 mL) was added PtO_2 , and the resulting reaction mixture was stirred at 35°C under H_2 at 35 Psi overnight. After being filtered, evaporated, diluted with water and basified with saturated $NaHCO_3$ (a.q.), the resulting mixture was extracted with DCM, and then the organic layer was dried, concentrated and purified by column chromatography (DCM / MeOH = 20 / 1) to give methyl 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)piperidine-3-carboxylate (600 mg, yield: 91%). ^1H -NMR ($CDCl_3$, 400 MHz) δ 7.79 (s, 2H), 7.70~7.73 (m, 1H), 7.36~7.39 (m, 1H), 7.11~7.15 (m,


2H), 6.03 (d, $J = 5.6$ Hz, 1H), 3.77~3.80 (m, 3H), 3.61~3.64 (m, 3H), 3.17~3.20 (m, 6H), 3.04 (s, 2H), 2.93~2.97 (m, 7H). MS (M+H)⁺: 518.

Step 5 - Synthesis of methyl 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-1-methylpiperidine-3-carboxylate



A solution of methyl 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)piperidine-3-carboxylate (400 mg, 0.8 mmol) in HCHO (4 mL) and HCOOH (4 mL) was heated to reflux for 1 h. After being concentrated, diluted with water and basified with saturated NaHCO₃ (aq), the mixture was extracted with DCM, and then the organic layer was dried, concentrated and purified by column chromatography (DCM / MeOH = 50 / 1) to give methyl 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-1-methylpiperidine-3-carboxylate (380 mg, yield: 92%). ¹H-NMR (CDCl₃, 400 MHz) δ 7.78~7.81 (m, 1H), 7.73 (s, 2H), 7.50~7.59 (m, 1H), 7.15 (d, $J = 8.8$ Hz, 2H), 5.72~5.87 (m, 1H), 3.95~3.98 (m, 1H), 3.61~3.78 (m, 4H), 3.47~3.49 (m, 1H), 3.16~3.42 (m, 6H), 3.08 (s, 1H), 3.00 (s, 1H), 2.78~2.90 (m, 3H), 2.35~2.65 (m, 5H), 2.26~2.28 (m, 1H). MS (M+H)⁺: 532.


Step 6 - Synthesis of 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-1-methylpiperidine-3-carboxylic acid



A solution of methyl 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-1-methylpiperidine-3-carboxylate (450 mg, 0.85 mmol) and LiOH.H₂O (178 mg, 4.3 mmol) in 1,4-dioxane : H₂O = 5 : 1 (18 mL) was heated to reflux and stirred for 1 h. Then the reaction mixture was cooled and diluted with water, followed by adjusting the solution to pH = 2~3. The resulting precipitate was collected by filtration, washed with water and dried to give 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-


methylmethylsulfonamido)benzofuran-5-yl)-1-methylpiperidine-3-carboxylic acid (400 mg, yield: 91%), which was used for the next step without further purification. MS (M+H)⁺: 518.

Step 7 - Synthesis of N-(2-fluoro-6-hydroxyphenyl)-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-1-methylpiperidine-3-carboxamide



A solution of 5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-1-methylpiperidine-3-carboxylic acid (100 mg, 0.2 mmol), HOBT (54 mg, 0.4 mmol) and EDCI·HCl (77 mg, 0.4 mmol) in DMF (5 mL) was stirred at room temperature for 1.5 hours. 2-amino-3-fluorophenol (76 mg, 0.6 mmol) was then added and the reaction continued to stir at room temperature overnight. The reaction was then poured into water, then extracted with DCM, washed with NaHCO₃, and dried over Na₂SO₄. After being concentrated, the residue was purified by column chromatography (DCM / MeOH = 20 / 1) to give pure N-(2-fluoro-6-hydroxyphenyl)-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-1-methylpiperidine-3-carboxamide (80 mg, yield: 66%), which was used for the next step without further purification. MS (M+H)⁺: 627.


Step 8 - Synthesis of 5-(5-(4-fluorobenzo[d]oxazol-2-yl)-1-methylpiperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (Example 1)




A solution of N-(2-fluoro-6-hydroxyphenyl)-5-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-1-methylpiperidine-3-carboxamide (70 mg, 0.11 mmol) and PTSA (11 mg, 0.06 mmol) in toluene (30 mL) was heated to reflux for 24 hours. After being concentrated, diluted with water and extracted with DCM, the organic layer was washed with saturated NaHCO₃, dried over Na₂SO₄ and concentrated. The residue was purified (DCM / CH₃OH = 10 / 1) to give pure 5-(5-(4-fluorobenzo[d]oxazol-2-yl)-1-methylpiperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (20 mg, yield: 29%). ¹H-NMR (CDCl₃, 400 MHz) δ 7.79 (d, J = 8.0

Hz, 3H), 7.43 (d, $J = 7.2$ Hz, 1H), 7.20~7.24 (m, 2H), 7.10~7.14 (m, 2H), 6.94~6.98 (m, 1H), 5.77 (s, 1H), 3.60~3.68 (m, 1H), 3.24~3.47 (m, 2H), 3.08~3.11 (m, 3H), 2.80~3.02 (m, 7H), 2.29~2.55 (m, 1H), 2.17~2.26 (m, 3H), 1.91~1.94 (m, 3H). MS ($M+H$)⁺: 609.

- 5 Example 2: (S)-5-(1-((7-fluoro-1H-indol-2-yl)sulfonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide



Step 1 - Synthesis of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(pyridin-3-yl)benzofuran-3-carboxamide




10

A mixture of 5-bromo-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (1.5 g, 3.29 mmol), pyridine-3-boronic acid (0.810 g, 6.59 mmol), potassium phosphate tribasic (5.59 g, 13.18 mmol) and 1,1'-bis(di-tert-butylphosphino)ferrocene palladium dichloride (0.215 g, 0.329 mmol) was suspended in DMF (15 ml) and heated at 120°C for 30 min. The reaction mixture was filtered and concentrated under vacuum, applied onto ISCO with normal phase and eluted with EtOAc/Hexane 30-100%. This resulted in 1.2 g (80 %) of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(pyridin-3-yl)benzofuran-3-carboxamide as a white solid. LC-MS (ES, m/z) $C_{23}H_{20}FN_3O_4S$: 453; Found: 454 [$M+H$]⁺.


15

- 20 Step 2 - Synthesis of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide




To a solution of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(pyridin-3-yl)benzofuran-3-carboxamide (1 g, 2.205 mmol) in MeOH (5 mL) and hydrochloric acid (37%, 0.5 ml) was added platinum(IV) oxide (20 mg, 0.088 mmol). The mixture was shaken under H₂ (45 Psi) for 2.5 hours. The reaction mixture was filtered and concentrated under vacuum. This resulted in 1.01 g (100%) of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethyl sulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide as a white solid. LC-MS (ES, m/z) C₂₃H₂₆FN₃O₄S : 459; Found: 460 [M+H]⁺.

Step 3 - Synthesis of (S)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide and (R)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide



2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (2.7 g, 5.88 mmol) was dissolved in DCM, applied onto IC 30 x 250 mm column and eluted with 35% MeOH (0.2% DEA)/CO₂ (100 bar, 35°C). This resulted in 0.9 g (33.3 %) of (S)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide as a white solid. LC-MS (ES, m/z) C₂₃H₂₆FN₃O₄S: 459; Found: 460 [M+H]⁺, and 1 g (37 %) of (R)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide as a white solid. LC-MS (ES, m/z) C₂₃H₂₆FN₃O₄S: 459; Found: 460 [M+H]⁺. The absolute configurations were determined by vibrational circular dichroism spectroscopy.


Step 4 - Synthesis of tert-butyl 7-fluoro-1H-indole-1-carboxylate



A mixture of 7-fluoro-1H-indole (3 g, 22.2 mmol), DIEA (8.6 g, 66.6 mmol) and DMAP (50 mg) in DCM (50 mL) was stirred at RT under N₂ atmosphere. Then (Boc)₂O (5.81 g, 26.6 mmol) was added, and the reaction mixture was stirred at RT for 16 h. The mixture was diluted with water, extracted with EtOAc, concentrated in vacuum and dried over Na₂SO₄. The residue was purified by column chromatography (PE : EA = 20 : 1) to afford the desired product tert-butyl 7-fluoro-1H-indole-1-carboxylate (4 g, yield: 77%). ¹H-NMR (CDCl₃, 400 MHz) δ


7.65 (s, 1H), 7.33 (d, $J = 8.0$ Hz, 1H), 7.16~7.17 (m, 1H), 7.02 (t, $J = 8.0$ Hz, 1H), 6.59 (s, 1H), 1.66 (s, 9H). MS (M+H)⁺: 236.

Step 5 - Synthesis of tert-butyl 2-(chlorosulfonyl)-7-fluoro-1H-indole-1-carboxylate




To a mixture of tert-butyl 7-fluoro-1H-indole-1-carboxylate (500 mg, 2.03 mmol) in THF (10 mL) was added n-BuLi (1 mL, 2.5 mmol) under N₂ atmosphere at -78°C. The mixture was stirred at -78°C for 1 h. Then SO₂ (g) was bubbled into the mixture for 10 min, and the reaction mixture was allowed to warm to 10°C over 2 h. After being concentrated in vacuum, the mixture was diluted with DCM (20 mL) followed by addition of NCS (460 mg, 3.05 mmol). The reaction was stirred at RT overnight. Water was added and the reaction mixture was extracted with DCM, dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography (PE : EA = 20 : 1) to afford the desired product of tert-butyl 2-(chlorosulfonyl)-7-fluoro-1H-indole-1-carboxylate (500 mg, yield: 65%). ¹H-NMR (CDCl₃, 400 MHz) δ 7.44~7.51 (m, 2H), 7.20 (d, $J = 8.0$ Hz, 2H), 1.63 (s, 9H). MS (M+H)⁺: 334 / 336.

Step 6 - Synthesis of (S)-tert-butyl 7-fluoro-2-((3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)piperidin-1-yl)sulfonyl)-1H-indole-1-carboxylate




A mixture of tert-butyl 2-(chlorosulfonyl)-7-fluoro-1H-indole-1-carboxylate (64 mg, 0.20 mmol), (S)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (70 mg, 0.15 mmol) and TEA (45 mg, 0.45 mmol) in DCM (6 mL) was stirred at RT for 6 h under N₂ atmosphere. The mixture was diluted with water, extracted with DCM, dried over Na₂SO₄ and concentrated to give the product (S)-tert-butyl 7-fluoro-2-((3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)piperidin-1-yl)sulfonyl)-1H-indole-1-carboxylate (100 mg, yield: 88%), which was used for the next step without further purification. MS (M+H)⁺: 757.

Step 7 - Synthesis of (S)-5-(1-((7-fluoro-1H-indol-2-yl)sulfonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (Example 2)




A mixture of (*S*)-tert-butyl 7-fluoro-2-((3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(*N*-methylmethylsulfonamido)benzofuran-5-yl)piperidin-1-yl)sulfonyl)-1*H*-indole-1-carboxylate (100 mg, 0.13 mmol) and TFA (1 mL) in CH₂Cl₂ (5 mL) was stirred at RT for 2 h. Then the mixture was concentrated. The residue was purified by prep-HPLC to afford the desired product of (*S*)-5-(1-((7-fluoro-1*H*-indol-2-yl)sulfonyl)piperidin-3-yl)-2-(4-fluorophenyl)-*N*-methyl-6-(*N*-methylmethylsulfonamido)benzofuran-3-carboxamide (50 mg, yield: 59%). ¹H-NMR (CDCl₃, 400 MHz) δ 9.10~9.55 (m, 1H), 7.77~7.83 (m, 3H), 7.44~7.50 (m, 2H), 7.01~7.17 (m, 5H), 5.76~5.81 (m, 1H), 3.50~4.16 (m, 3H), 3.12~3.33 (m, 6H), 2.90~3.02 (m, 3H), 2.50~2.76 (m, 2H), 1.73~2.02 (m, 4H). MS (M+H)⁺: 657.

Example 3: (*R*)-5-(1-((7-fluoro-1*H*-indol-2-yl)sulfonyl)piperidin-3-yl)-2-(4-fluorophenyl)-*N*-methyl-6-(*N*-methylmethylsulfonamido)benzofuran-3-carboxamide




Step 1 - Synthesis of (*R*)-tert-butyl 7-fluoro-2-((3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(*N*-methylmethylsulfonamido)benzofuran-5-yl)piperidin-1-yl)sulfonyl)-1*H*-indole-1-carboxylate



A mixture of tert-butyl 2-(chlorosulfonyl)-7-fluoro-1*H*-indole-1-carboxylate (64 mg, 0.20 mmol), (*R*)-2-(4-fluorophenyl)-*N*-methyl-6-(*N*-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (70 mg, 0.15 mmol) and TEA (45 mg, 0.45 mmol) in DCM (6 mL) was stirred at RT for 6 h under N₂ atmosphere. The mixture was diluted with water, extracted with DCM, dried over Na₂SO₄ and concentrated to give the product (*R*)-tert-butyl 7-fluoro-2-((3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(*N*-methylmethylsulfonamido)


benzofuran-5-yl)piperidin-1-yl)sulfonyl)-1H-indole-1-carboxylate (100 mg, yield: 88%), which was used for the next step without further purification. MS (M+H)⁺: 757.

Step 2 - Synthesis of (R)-5-(1-((7-fluoro-1H-indol-2-yl)sulfonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide




A mixture of (R)-tert-butyl 7-fluoro-2-((3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethanesulfonamido)benzofuran-5-yl)piperidin-1-yl)sulfonyl)-1H-indole-1-carboxylate (100 mg, 0.13 mmol) and TFA (1 mL) in CH₂Cl₂ (5 mL) was stirred at RT for 2 h. Then the mixture was concentrated. The residue was purified by prep-HPLC to afford the desired product of (R)-5-(1-((7-fluoro-1H-indol-2-yl)sulfonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (50 mg, yield: 59%). ¹H-NMR (CDCl₃, 400 MHz) δ 9.10~9.55 (m, 1H), 7.77~7.83 (m, 3H), 7.44~7.50 (m, 2H), 7.01~7.17 (m, 5H), 5.76~5.81 (m, 1H), 3.50~4.16 (m, 3H), 3.12~3.33 (m, 6H), 2.90~3.02 (m, 3H), 2.50~2.76 (m, 2H), 1.73~2.02 (m, 4H). MS (M+H)⁺: 657.

Example 4: (R)-5-(1-(4-cyanobenzo[d]oxazol-2-yl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide




Step 1 - Synthesis of 2-mercaptobenzo[d]oxazole-4-carbonitrile



A mixture of 2-amino-3-hydroxybenzonitrile (200 mg, 1.22 mmol), TCDI (260 mg, 1.46 mmol) and in THF (10 mL) was stirred at RT for 6 h under N₂ atmosphere. The mixture was diluted with 1N HCl, extracted with EtOAc, dried over Na₂SO₄ and concentrated in vacuum to give the product 2-mercaptobenzo[d]oxazole-4-carbonitrile (200 mg, yield: 80%),

which was used for the next step without further purification. $^1\text{H-NMR}$ (CDCl_3 , 400 MHz) δ 7.45 (t, $J = 8.0$ Hz, 2H), 7.25 (t, $J = 8.0$ Hz, 1H). MS ($\text{M}+\text{H}$) $^+$: 177.


Step 2 - Synthesis of 2-chlorobenzo[d]oxazole-4-carbonitrile



To a mixture of 2-mercaptobenzo[d]oxazole-4-carbonitrile (100 mg, 0.57 mmol) in SOCl_2 (2 mL) was added DMF (1 drop). The mixture was heated to 80°C for 20 min. The reaction mixture was concentrated in vacuum, diluted with NaHCO_3 (aq), extracted with EtOAc, dried over Na_2SO_4 , and concentrated. The residue was purified by column chromatography (PE : EA = 5 : 1) to give the product of 2-chlorobenzo[d]oxazole-4-carbonitrile (60 mg, yield: 60%).


$^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ 7.75 (d, $J = 8.0$ Hz, 2H), 7.70 (d, $J = 8.0$ Hz, 1H), 7.47 (t, $J = 8.0$ Hz, 1H). MS ($\text{M}+\text{H}$) $^+$: 179 / 181.

Step 3 - Synthesis of (R)-5-(1-(4-cyanobenzo[d]oxazol-2-yl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (Example 4)




A mixture of 2-chlorobenzo[d]oxazole-4-carbonitrile (33 mg, 0.18 mmol), (R)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (70 mg, 0.15 mmol) and K_2CO_3 (63 mg, 1.98 mmol) in DMF (5 mL) was stirred at RT overnight under N_2 atmosphere. The mixture was diluted with water, extracted with EtOAc, dried over Na_2SO_4 and concentrated in vacuum. The residue was purified by prep-HPLC to afford the desired product of (R)-5-(1-(4-cyanobenzo[d]oxazol-2-yl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (50 mg, yield: 56%). $^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ 7.83~7.89 (m, 3H), 7.36~7.62 (m, 3H), 7.18~7.22 (m, 2H), 6.97~6.99 (m, 1H), 5.78 (br s, 1H), 4.39~4.42 (m, 2H), 3.22~3.55 (m, 3H), 2.97~3.16 (m, 8H), 1.79~2.23 (m, 5H). MS ($\text{M}+\text{H}$) $^+$: 602.

Example 5: (S)-5-(1-(4-cyanobenzo[d]oxazol-2-yl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide



Synthesis of (S)-5-(1-(4-cyanobenzo[d]oxazol-2-yl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide




5 A mixture of 2-chlorobenzo[d]oxazole-4-carbonitrile (33 mg, 0.18 mmol), (S)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (70 mg, 0.15 mmol) and K₂CO₃ (63 mg, 1.98 mmol) in DMF (5 mL) was stirred at RT overnight under N₂ atmosphere. The mixture was diluted with water, extracted with EtOAc, dried over Na₂SO₄ and concentrated in vacuum. The residue was purified by prep-HPLC to

10 afford the desired product of (S)-5-(1-(4-cyanobenzo[d]oxazol-2-yl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (50 mg, yield: 56%). ¹H-NMR (CDCl₃, 400MHz) δ 7.83~7.89 (m, 3H), 7.36~7.62 (m, 3H), 7.18~7.22 (m, 2H), 6.97~6.99 (m, 1H), 5.78 (brs, 1H), 4.39~4.42 (m, 2H), 3.22~3.55 (m, 3H), 2.97~3.16 (m, 8H), 1.79~2.23 (m, 5H). MS (M+H)⁺: 602.


15

Examples 6 and 7: 5-(4-(7-fluoro-1H-indole-2-carbonyl)morpholin-2-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)




Step 1 - Synthesis of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)-5-vinylbenzofuran-3-carboxamide

20



A mixture of 5-bromo-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (10 g, 21.96 mmol), tributyl(vinyl)stannane (14 g, 44.15 mmol) and Pd(PPh₃)₄ (2.54 g, 2.20 mmol) in dioxane (150 mL) was stirred at 90°C for 20 hours under N₂ protection. Then the mixture was cooled to room temperature, diluted with EA (100 mL) and filtered through a Celite pad. The combined organic phase was washed with water and brine, dried over Na₂SO₄ and concentrated. The residue was purified by silica gel column chromatography (PE : EA = 2 : 1) to afford the desired product of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-vinylbenzofuran-3-carboxamide (8.8 g, yield: 79.5%). ¹H-NMR (CDCl₃, 400 MHz) δ 8.06 (s, 1H), 7.90 (dd, *J* = 5.2, 8.8 Hz, 2H), 7.51 (s, 1H), 7.19 (t, *J* = 8.4 Hz, 2H), 7.09 (dd, *J* = 11.2, 17.6 Hz, 1H), 5.84 (d, *J* = 17.6 Hz, 2H), 5.41 (d, *J* = 11.2 Hz, 1H), 3.28 (s, 3H), 2.97~3.04 (m, 6H). MS (M+H)⁺: 403.


Step 2 - Synthesis of 5-(1,2-dihydroxyethyl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide



A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-vinylbenzofuran-3-carboxamide (4 g, 9.94 mmol), NMO (3.49 g, 29.81 mmol) and OsO₄ (250 mg, 0.98 mmol) in THF / MeOH / H₂O (20 mL / 20 mL / 5 mL) was stirred at room temperature for 2 hours. Then Na₂SO₃ (5 g, 39.7 mmol) was added, and the reaction mixture was extracted with EA (10 mL * 3). The combined organic layer was washed with brine (30 mL), dried over Na₂SO₄ and concentrated. The residue was purified by silica gel column chromatography (DCM : MeOH = 10 : 1) to afford the product of 5-(1,2-dihydroxyethyl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (3.5 g, yield: 80.8%). ¹H-NMR (CDCl₃, 400 MHz) δ 7.98~8.05 (m, 1H), 7.88~7.97 (m, 2H), 7.44 (s, 1H), 7.17 (t, *J* = 8.4 Hz, 2H), 6.15~6.29 (m, 1H), 5.39 (dd, *J* = 3.6, 7.6 Hz, 1H), 5.22 (d, *J* = 4.4 Hz, 1H), 3.91~3.99 (m,


1H), 3.81~3.90 (m, 1H), 3.44~3.79 (m, 2H), 3.25~3.37 (m, 3H), 2.82~3.12 (m, 7H). MS (M+H)⁺: 436.

Step 3 - Synthesis of 2-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethanesulfonamido)benzofuran-5-yl)-2-hydroxyethyl methanesulfonate



To a solution of 5-(1,2-dihydroxyethyl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (3.5 g, 8.02 mmol) in pyridine (30 mL) was added MsCl (1.5 g, 13.09 mmol). The reaction mixture was stirred at room temperature for 2 hours and then the reaction mixture was diluted with water, and then extracted with EA (20 mL * 8). The combined organic layer was washed with brine (150 mL), dried over Na₂SO₄ and concentrated, the residue was purified by silica gel column chromatography (DCM : MeOH = 20 : 1) to afford the product 2-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethanesulfonamido)benzofuran-5-yl)-2-hydroxyethyl methanesulfonate (3.8 g, yield: 92.2%). ¹H-NMR (CDCl₃, 400 MHz) δ 8.03~8.09 (m, 1H), 7.91~8.02 (m, 2H), 7.40~7.54 (m, 1H), 7.19 (t, *J* = 8.4 Hz, 2H), 6.14~5.91 (m, 1H), 5.48~5.68 (m, 1H), 4.39~4.72 (m, 2H), 3.29~3.39 (m, 3H), 2.97~3.15 (m, 9H). MS (M+H)⁺: 515.


Step 4 - Synthesis of 2-(4-fluorophenyl)-5-(1-hydroxy-2-((2-hydroxyethyl)amino)ethyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide



To a solution of 2-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethanesulfonamido)benzofuran-5-yl)-2-hydroxyethyl methanesulfonate (3.8 g, 7.38 mmol) in DMF (20 mL) was added 2-aminoethanol (2.71 g, 44.32 mmol) and K₂CO₃ (3.06 g, 22.16 mmol). The reaction mixture was stirred at 80°C for 40 hours. Then the reaction mixture was concentrated to afford the crude product 2-(4-fluorophenyl)-5-(1-hydroxy-2-((2-hydroxyethyl)amino)ethyl)-N-


methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide, which was used for next step without purification. MS (M+H)⁺: 480.

Step 5 - Synthesis of tert-butyl (2-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-2-hydroxyethyl)(2-hydroxyethyl)carbamate



A mixture of 2-(4-fluorophenyl)-5-(1-hydroxy-2-((2-hydroxyethyl)amino)ethyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (crude from previous step) and (Boc)₂O (15 g, 68.7 mmol) in THF (30 mL) was stirred at room temperature for 18 hours under N₂ protection. Then the mixture was quenched with water and extracted with EA (20 mL * 5). The organic phase was washed with water and brine, dried over Na₂SO₄ and concentrated. The residue was purified by silica gel column chromatography (DCM : MeOH = 20 : 1) to afford the product of tert-butyl (2-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-2-hydroxyethyl)(2-hydroxyethyl)carbamate (2.5 g, yield: 58.1% for 2 steps). ¹H-NMR (CDCl₃, 400 MHz) δ 7.71~8.14 (m, 3H), 7.41 (d, *J* = 15.6 Hz, 1H), 7.17 (d, *J* = 3.6 Hz, 2H), 5.95~6.33 (m, 1H), 5.35~5.64 (m, 1H), 3.59~3.95 (m, 4H), 3.50 (d, *J* = 12.4 Hz, 1H), 3.26~3.43 (m, 4H), 3.15 (br. s., 1H), 2.94~3.10 (m, 5H), 1.39~1.54 (m, 9H). MS (M+H)⁺: 580.


Step 6 - Synthesis of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(morpholin-2-yl)benzofuran-3-carboxamide



Tert-butyl (2-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-2-hydroxyethyl)(2-hydroxyethyl)carbamate (700 mg, 1.2 mmol) in 70% H₂SO₄ aqueous (20 mL) was stirred at room temperature for 12 hours under N₂ protection. Then the mixture was quenched with water, adjusted to pH ~8, and extracted with EA (20 mL * 5). The combined organic layer was washed with brine (30 mL), dried over


Na₂SO₄ and concentrated. The residue was purified by silica gel column chromatography (DCM : MeOH = 20 : 1) to afford the product of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)-5-(morpholin-2-yl)benzofuran-3-carboxamide (350 mg, yield: 62.8%). ¹H-NMR (CDCl₃, 400 MHz) δ 8.01 (br s, 1H), 7.87~7.97 (m, 2H), 7.40~7.55 (m, 1H), 7.18 (t, *J* = 8.4 Hz, 2H), 5.85~6.04 (m, 1H), 4.87~5.12 (m, 1H), 3.96~4.10 (m, 1H), 3.76~3.90 (m, 1H), 3.19~3.38 (m, 4H), 2.98~3.15 (m, 8H), 2.76~2.97 (m, 2H). MS (M+H)⁺: 462.

Step 7 - Synthesis of tert-butyl 7-fluoro-2-(2-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethanesulfonamido)benzofuran-5-yl)morpholine-4-carbonyl)-1H-indole-1-carboxylate



A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)-5-(morpholin-2-yl)benzofuran-3-carboxamide (150 mg, 0.33 mmol), 1-(tert-butoxycarbonyl)-7-fluoro-1H-indole-2-carboxylic acid (91 mg, 0.33 mmol), HATU (371 mg 0.98 mmol) and Et₃N (165 mg 1.6 mmol) in DMF (2 mL) was stirred at RT overnight under N₂ protection. Then the mixture was diluted with H₂O (20 mL) and extracted with EtOAc. The organic layer was washed with water, brine, dried over Na₂SO₄, and concentrated. The residue was purified by prep-TLC (PE : EA= 1 : 1) to give the product of tert-butyl 7-fluoro-2-(2-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethanesulfonamido)benzofuran-5-yl) morpholine-4-carbonyl)-1H-indole-1-carboxylate (180 mg, yield: 76%). MS (M+H)⁺: 723.

Step 8 - Synthesis of 5-(4-(7-fluoro-1H-indole-2-carbonyl)morpholin-2-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (Enantiomers 1 and 2)




To a solution of tert-butyl 7-fluoro-2-(2-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)morpholine-4-carbonyl)-1H-indole-1-carboxylate (230 mg, 0.32 mmol) in dioxane (2 mL) was added HCl solution in dioxane (5 mL, 4 M) at RT. The mixture was stirred at RT for 5 hours. The mixture was diluted with water and extracted with DCM. The organic layers were washed with brine, dried over Na₂SO₄, and concentrated. The residue was purified by prep-HPLC and SFC to give two single enantiomers.


Example 6 (enantiomer 1, peak 1 on SFC, AS-H_S_3_5_40_3ML_8MIN_15CM, HPLC_RT= 5.097 min) (60 mg, yield: 30 %). ¹H-NMR (CDCl₃, 400 MHz) δ 9.38 (br s, 1H), 8.10~8.17 (m, 1H), 7.84~7.98 (m, 2H), 7.33~7.57 (m, 2H), 7.15~7.23 (m, 2H), 6.87~7.09 (m, 3H), 5.88 (br s, 1H), 4.87~5.10 (m, 2H), 4.51~4.75 (m, 3H), 4.10~4.25 (m, 1H), 3.80~3.95 (m, 1H), 3.31 (s, 3H), 2.88~3.14 (m, 6 H). MS (M+H)⁺: 623.

Example 7 (enantiomer 2, peak 2 on SFC, AS-H_S_3_5_40_3ML_8MIN_15CM, HPLC_RT= 5.582 min) (60 mg, yield: 30 %). ¹H-NMR (CDCl₃, 400 MHz) δ 9.38 (br s, 1H), 8.10~8.17 (m, 1H), 7.84~7.98 (m, 2H), 7.33~7.57 (m, 2H), 7.15~7.23 (m, 2H), 6.87~7.09 (m, 3H), 5.88 (br s, 1H), 4.87~5.10 (m, 2H), 4.51~4.75 (m, 3H), 4.10~4.25 (m, 1H), 3.80~3.95 (m, 1H), 3.31 (s, 3H), 2.88~3.14 (m, 6 H). MS (M+H)⁺: 623.

Examples 8 and 9: 5-(4-(4-fluoro-1-methyl-1H-indole-2-carbonyl)morpholin-2-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)



Synthesis of 5-(4-(4-fluoro-1-methyl-1H-indole-2-carbonyl)morpholin-2-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (enantiomer 1) and 5-(4-(4-fluoro-1-methyl-1H-indole-2-carbonyl)morpholin-2-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (enantiomer 2)




A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)-5-(morpholin-2-yl)benzofuran-3-carboxamide (150 mg, 0.33 mmol), 4-fluoro-1-methyl-1H-indole-2-carboxylic acid (63 mg, 0.33 mmol), HATU (371 mg 0.98 mmol) and Et₃N (165 mg 1.6 mmol) in DMF (2 mL) was stirred at RT overnight under N₂ protection. Then the reaction mixture was diluted with H₂O (20 mL) and extracted with DCM, the organic layer was washed with water, brine, dried over Na₂SO₄ and concentrated. The residue was purified by prep-HPLC and SFC to give two single enantiomers.

Example 8 (enantiomer 1, peak 1 on SFC, AS-H_S_3_5_40_2.5ML_6MIN_25CM, HPLC_RT= 2.40 min) (80 mg, yield: 38 %). ¹H-NMR (CDCl₃, 400 MHz) δ 8.02~8.13 (m, 1H), 7.84~7.96 (m, 2H), 7.30~7.55 (m, 1H), 7.09~7.22 (m, 4H), 6.64~6.86 (m, 2H), 5.97 (br s, 1H), 4.89~5.27 (m, 1H), 4.03~4.76 (m, 3H), 3.78~3.97 (m, 4H), 3.29 (s, 3H), 2.64~3.09 (m, 8H). MS (M+H)⁺: 637.


Example 9 (enantiomer 2, peak 2 on SFC, AS-H_S_3_5_40_2.5ML_6MIN_25CM, HPLC_RT= 3.07 min) (80 mg, yield: 38 %). ¹H-NMR (CDCl₃, 400 MHz) δ 8.02~8.13 (m, 1H), 7.84~7.96

(m, 2H), 7.30~7.55 (m, 1H), 7.09~7.22 (m, 4 H), 6.64~6.86 (m, 2H), 5.97 (br s, 1H), 4.89~5.27 (m, 1H), 4.03~4.76 (m, 3H), 3.78~3.97 (m, 4H), 3.29 (s, 3H), 2.64~3.09 (m, 8H). MS (M+H)⁺: 637.

- 5 Examples 10 and 11: 5-(4-(benzo[d]oxazol-2-yl)morpholin-2-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)




Synthesis of 5-(4-(benzo[d]oxazol-2-yl)morpholin-2-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide and 5-(4-(benzo[d]oxazol-2-yl)morpholin-2-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide




A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(morpholin-2-yl)benzofuran-3-carboxamide (229 mg, 0.50 mmol), 2-chlorobenzo[d]oxazole (91 mg, 0.595 mmol) and K₂CO₃ (206 mg 1.49 mmol) in DMF (5 mL) was stirred at RT for 4 h under N₂ protection. Then the reaction mixture was diluted with H₂O (20 mL) and extracted with EtOAc. The organic layer was washed with water, brine, dried over Na₂SO₄ and concentrated. The residue was purified by prep-HPLC and SFC to give two single enantiomers. Example 10 (enantiomer 1, peak 1 on SFC, OJ-H_3UM_5_5_40_4ML_3MIN, HPLC_RT= 1.385 min) (100 mg, yield: 34 %). ¹H-NMR (CDCl₃, 400 MHz) δ 8.09 (br s, 1H), 7.88~7.97 (m, 2H), 7.53 (s, 1H), 7.32~7.40 (m, 1H), 7.24~7.31 (m, 1H), 7.13~7.23 (m, 3H), 7.04 (q, J=7.6 Hz, 1H), 5.95 (br s, 1H), 4.99~5.26 (m, 1H), 4.07~4.29 (m, 3 H), 3.85~4.03 (m, 1 H), 3.36~3.52 (m, 2H), 3.17 (s, 3H), 2.96~3.07 (m, 6H). MS (M+H)⁺: 579.

Example 11 (enantiomer 2, peak 2 on SFC, OJ-H_3UM_5_5_40_4ML_3MIN, HPLC_RT= 1.765 min) (100 mg, yield: 34 %). $^1\text{H-NMR}$ (CDCl_3 , 400 MHz) δ 8.09 (br s, 1H), 7.88~7.97 (m, 2H), 7.53 (s, 1H), 7.32~7.40 (m, 1H), 7.24~7.31 (m, 1H), 7.13~7.23 (m, 3H), 7.04 (q, $J=7.6$ Hz, 1H), 5.95 (br s, 1H), 4.99~5.26 (m, 1H), 4.07~4.29 (m, 3H), 3.85~4.03 (m, 1H), 3.36~3.52 (m, 2H), 3.17 (s, 3H), 2.96~3.07 (m, 6H). MS ($\text{M}+\text{H}^+$): 579.

Example 12: 5-((5S)-5-(4-fluorobenzo[d]oxazol-2-yl)-1-methylpyrrolidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide




10 Step 1 - Synthesis of (S)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate



PCC (52.9 g, 244.63 mmol) was added into a solution of (2S,4R)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate (10 g, 81.54 mmol) in DCM (300 mL) under N_2 and the mixture was stirred for 48 hours. After being filtered and concentrated, the residue was purified by column chromatography eluted with PE : EtOAc = 4 : 1 to afford (S)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate (11 g, yield: 55.5%). $^1\text{H-NMR}$ (CDCl_3 , 400 MHz) δ 4.67~4.79 (m, 1H), 3.86 (d, $J=12.0$ Hz, 2H), 3.73 (s, 3H), 2.90~2.93 (m, 1H), 2.56 (d, $J=20.0$ Hz, 1H), 1.45 (s, 9H). MS ($\text{M}+\text{H}^+$): 244.


20 Step 2 - Synthesis of (S)-1-tert-butyl 2-methyl 4-(trifluoromethylsulfonyloxy)-1H-pyrrole-1,2(2H,5H)-dicarboxylate



LiHMDS (1.51 g, 9.04 mmol) was added into a solution of (S)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate (2 g, 8.22 mmol) in dry THF (20 mL) under N_2 dropwise at -78°C and the mixture was stirred for 0.5 hours. 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (3.23 g, 9.04 mmol) in dry THF (20 mL) was added into the reaction mixture under N_2 dropwise at -78°C and stirred for 2 hours. Then the


reaction mixture was stirred at RT for 12 hours. After being diluted with NH_4Cl (a.q.) and extracted with EtOAc (200 mL* 3), the organics were washed with brine and dried over Na_2SO_4 . After being filtered and concentrated in vacuo, the residue was purified by column chromatography and eluted with PE : EtOAc = 20 : 1 to afford (S)-1-tert-butyl 2-methyl 4-(trifluoromethylsulfonyloxy)-1H-pyrrole-1,2(2H,5H)-dicarboxylate (1.1 g, yield: 35.5%). ^1H -NMR (CDCl_3 , 400 MHz) δ 5.69~5.74 (m, 1H), 4.99~5.08 (m, 1H), 4.23~4.41 (m, 2H), 3.75 (s, 3H), 1.47 (s, 9H). MS ($\text{M}+\text{H}^+$): 376.

Step 3 - Synthesis of (S)-1-tert-butyl 2-methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole-1,2(2H,5H)-dicarboxylate



To a degassed solution of (S)-1-tert-butyl 2-methyl 4-(trifluoromethylsulfonyloxy)-1H-pyrrole-1,2(2H,5H)-dicarboxylate (200 mg, 0.53 mmol) and bis(pinacolato)diboron (148 mg, 0.58 mmol) in dry dioxane (3 mL) was added $\text{Pd}(\text{dppf})\text{Cl}_2$ (1 mg) and KOAc (162 mg, 165 mmol) under N_2 . The mixture was heated to 100°C and then stirred overnight. The reaction mixture was cooled to RT and filtered. The filtrate was diluted with EtOAc (50 mL), washed with H_2O , brine, dried over Na_2SO_4 . After being concentrated, the residue was purified by prep-TLC (PE: EtOAc = 1 : 1) to afford (S)-1-tert-butyl 2-methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole-1,2(2H,5H)-dicarboxylate (160 mg, yield: 85%). ^1H -NMR (CDCl_3 , 400 MHz) δ 6.27~6.33 (m, 1H), 5.07~5.10 (m, 1H), 4.26~4.32 (m, 2H), 3.69 (s, 3H), 1.42 (s, 9H), 1.21 (s, 12H). MS ($\text{M}+\text{H}^+$): 354.


Step 4 - Synthesis of (S)-1-tert-butyl 2-methyl 4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-1H-pyrrole-1,2(2H,5H)-dicarboxylate



To a degassed solution of 5-bromo-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (120 mg, 0.26 mmol) and (S)-1-tert-butyl


2-methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole-1,2(2H,5H)-dicarboxylate (102 mg, 0.29 mmol) in dry dioxane (3 mL) was added Pd(dppf)Cl₂ (2 mg) and K₃PO₄ (112 mg, 1.05 mmol) under N₂. The mixture was heated to 100°C and then stirred overnight. The reaction mixture was cooled to RT and filtered. The filtrate was diluted with EtOAc (50 mL), washed with H₂O, brine, and dried over Na₂SO₄. After being concentrated, the residue was purified by prep-HPLC (PE : EtOAc = 1 : 2) to give the product of (S)-1-tert-butyl 2-methyl 4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-1H-pyrrole-1,2(2H,5H)-dicarboxylate (50 mg, yield: 31.6%). ¹H-NMR (CDCl₃, 400 MHz) δ 7.86~7.92 (m, 2H), 7.77~7.81 (m, 1H), 7.55 (s, 1H), 7.17~7.22 (m, 2H), 6.04~6.06 (m, 2H), 5.12~5.21 (m, 1H), 4.57~4.67 (m, 2H), 3.78 (s, 3H), 3.25 (s, 3H), 3.00~3.02 (m, 6H), 1.23 (s, 9H). MS (M+H)⁺: 602.

Step 5 - Synthesis of (2S)-1-tert-butyl 2-methyl 4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)pyrrolidine-1,2-dicarboxylate




To a solution of (S)-1-tert-butyl 2-methyl 4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-1H-pyrrole-1,2(2H,5H)-dicarboxylate (460 mg, 0.76 mmol) in MeOH (10 mL), Pd/C (200 mg) was added and the resulting reaction mixture was stirred under 40 psi of H₂ atmosphere for 24 h at 25°C. Then the reaction mixture was filtered, and the filtrate was evaporated to give the crude product of (2S)-1-tert-butyl 2-methyl 4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)pyrrolidine-1,2-dicarboxylate (400 mg, yield: 86.7%). ¹H-NMR (CDCl₃, 400 MHz) δ 7.61~7.94 (m, 3H), 7.36~7.47 (m, 1H), 7.10~7.14 (m, 2H), 5.88~6.13 (m, 1H), 4.28~4.35 (m, 1H), 3.91~4.01 (m, 2H), 3.66~3.72 (m, 4H), 3.37~3.50 (m, 1H), 3.19~3.32 (m, 2H), 2.94~2.98 (m, 6H), 2.57~2.78 (m, 1H), 1.88~2.14 (m, 1H), 1.39 (s, 9H). MS (M+H)⁺: 604.

Step 6 - Synthesis of (2S)-methyl 4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)pyrrolidine-2-carboxylate




TFA (0.5 mL) was added into a solution of (2*S*)-1-tert-butyl 2-methyl 4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)pyrrolidine-1,2-dicarboxylate (200 mg, 0.33 mmol) in DCM (5 mL) under N₂ dropwise at 0°C and stirred for 6 hours. After being diluted with NaHCO₃ (a.q.) and extracted with EtOAc (50 mL * 3), the combined organic phase was washed with brine, dried over Na₂SO₄ and concentrated to give the desired product of (2*S*)-methyl 4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)pyrrolidine-2-carboxylate (150 mg, yield: 89.8%). MS (M+H)⁺: 504.

Step 7 - Synthesis of (2*S*)-methyl 4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-1-methylpyrrolidine-2-carboxylate




A solution of (2*S*)-methyl 4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)pyrrolidine-2-carboxylate (50 mg, 0.09 mmol), CH₃CO₂Na (8 mg, 0.09 mmol) and HCHO (8 mg, 0.09 mmol) in MeOH (5 mL) was stirred at RT for 1 h under N₂. Then TEA (3 drops) and NaBH(OAc)₃ (105 mg, 0.5 mmol) were added to the mixture. After being stirred for 12 h, the mixture was diluted with water and extracted with DCM. The combined organic phases were washed with brine, dried over Na₂SO₄, filtered and evaporated to give (2*S*)-methyl 4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-1-methylpyrrolidine-2-carboxylate (40 mg, yield: 78.4%). MS (M+H)⁺: 518.

Step 8 - Synthesis of (2*S*)-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-1-methylpyrrolidine-2-carboxylic acid



To a solution of (2*S*)-methyl 4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(*N*-methylmethylsulfonamido)benzofuran-5-yl)-1-methylpyrrolidine-2-carboxylate (100 mg, 0.19 mmol) in dioxane (5 mL) and water (3 mL), LiOH·H₂O (82 mg, 1.93 mmol) was added, and the mixture was stirred overnight at 20°C. After being concentrated, H₂O was added, the mixture was extracted with ether, and the aqueous phase was acidified by 1 N HCl. Then the mixture was extracted by EtOAc (50 mL*3), and the combined organic phase was washed with brine, dried over Na₂SO₄ and concentrated. The residue was dried to give the desired product of (2*S*)-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(*N*-methylmethylsulfonamido)benzofuran-5-yl)-1-methylpyrrolidine-2-carboxylic acid (90 mg, yield: 91.8%). ¹H-NMR (CDCl₃, 400 MHz) δ 7.91~7.95 (m, 2H), 7.83~7.86 (m, 2H), 7.22~7.26 (m, 2H), 4.45~4.52 (m, 1H), 4.00~4.12 (m, 1H), 3.65~3.73 (m, 2H), 3.46~3.57 (m, 1H), 3.28~3.34 (m, 3H), 3.07 (d, *J* = 8.0 Hz, 3H), 2.96~3.01 (m, 6H), 2.18~2.30 (m, 1H). MS (M+H)⁺: 504.

Step 9 - Synthesis of (2*S*)-*N*-(2-fluoro-6-hydroxyphenyl)-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(*N*-methylmethylsulfonamido)benzofuran-5-yl)-1-methylpyrrolidine-2-carboxamide




(2*S*)-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(*N*-methylmethylsulfonamido)benzofuran-5-yl)-1-methylpyrrolidine-2-carboxylic acid (57 mg, 0.11 mmol), HOBT (17 mg, 0.12 mmol), EDCI (33 mg, 0.16 mmol) and TEA (35 mg, 0.33 mmol) were dissolved in dry DMF (3 mL). The resulting solution was stirred for 30 minutes. Then 2-amino-3-fluorophenol (22 mg, 0.16 mmol) was added to the mixture. The mixture was stirred at 20°C overnight. Then H₂O was added, and the reaction mixture filtered to give the crude solid. The crude product was purified by prep-TLC (DCM : MeOH = 20 : 1) to give (2*S*)-*N*-(2-fluoro-6-hydroxyphenyl)-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(*N*-methylmethylsulfonamido)benzofuran-5-yl)-1-

methylpyrrolidine-2-carboxamide (30 mg, yield: 43.4 %), which was used for the next step without further purification. MS (M+H)⁺: 613.


Step 10 - Synthesis of 5-((5S)-5-(4-fluorobenzo[d]oxazol-2-yl)-1-methylpyrrolidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (Example

5 12)




4-methylbenzene sulfonic acid (10 mg, 0.05 mmol) was added to a solution of (2S)-N-(2-fluoro-6-hydroxyphenyl)-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-1-methylpyrrolidine-2-carboxamide (30 mg, 0.05 mmol) in toluene (1 mL) under N₂. The mixture was stirred at reflux overnight. After being concentrated in vacuo, the residue was purified by prep-HPLC to give the product of 5-((5S)-5-(4-fluorobenzo[d]oxazol-2-yl)-1-methylpyrrolidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (20 mg, yield: 68.9%). ¹H-NMR (MeOD, 400 MHz) δ 7.87~7.99 (m, 4H), 7.49~7.58 (m, 2H), 7.22~7.29 (m, 3H), 5.25~5.41 (m, 1H), 4.54~4.72 (m, 1H), 3.95~4.22 (m, 1H), 3.61~3.92 (m, 1H), 3.21~3.38 (m, 6H), 3.10~3.17 (m, 4H), 3.08~2.87 (m, 3H), 2.70~2.80 (m, 1H). MS (M+H)⁺: 595.

Example 13: 5-(6-(4-fluoro-1H-indol-2-yl)piperazin-2-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido) benzofuran-3-carboxamide




Step 1 - Synthesis of tert-butyl 4-fluoro-1H-indole-1-carboxylate



To a solution of 4-fluoro-1H-indole (150 g, 1.11 mol) and DMAP (4.5 g, 3%wt) in THF (2.5 L) was added (Boc)₂O (255 g, 1.16 mol) dropwise. The mixture was stirred at room


temperature overnight. The organic solvent was removed in vacuum, and the residue was purified by column chromatography (PE) to give tert-butyl 4-fluoro-1H-indole-1-carboxylate (250 g, yield: 96%). $^1\text{H-NMR}$ (CDCl_3 , 400 MHz) δ 7.92 (d, $J = 8.4$ Hz, 1H), 7.55 (d, $J = 3.6$ Hz, 1H), 7.23 (m, 1H), 6.90 (m, 1H), 6.66 (d, $J = 3.6$ Hz, 1H), 1.67 (s, 9H). MS ($\text{M}+\text{H}^+$): 236.

5 Step 2 - Synthesis of (1-(tert-butoxycarbonyl)-4-fluoro-1H-indol-2-yl)boronic acid



To a solution of diisopropylamine (175 mL, 1.25 mol) in THF (800 mL) at 0°C was added n-BuLi (500 mL, 1.25 mol) dropwise. The mixture was stirred at 0°C for 40 minutes. Then the mixture was cooled to -78°C . Tert-butyl 4-fluoro-1H-indole-1-carboxylate (118 g, 0.50 mol) in THF (300 mL) was added dropwise, followed by triisopropyl borate (231 mL, 1.00 mol). The mixture was stirred at -78°C for another 40 min. The reaction was monitored by HPLC. When the reaction was completed, the reaction was quenched with NH_4Cl (sat. 500 mL). Then the mixture was adjusted to pH = 6 with 1 N HCl, extracted with EtOAc (2000 mL) and the combined organic layers were washed with brine (500 mL), dried over Na_2SO_4 , filtered and concentrated. The obtained solid was recrystallized with EtOAc and PE to give (1-(tert-butoxycarbonyl)-4-fluoro-1H-indol-2-yl)boronic acid (93 g, yield: 64%). $^1\text{H-NMR}$ (CDCl_3 , 400 MHz) δ 7.77 (d, $J = 8.4$ Hz, 1H), 7.57 (s, 1H), 7.44 (s, 2H), 7.24 (m, 1H), 6.90 (m, 1H), 1.66 (s, 9H). MS ($\text{M}+\text{H}^+$): 280.


15 Step 3 - Synthesis of tert-butyl 2-(6-chloropyrazin-2-yl)-4-fluoro-1H-indole-1-carboxylate



20 Pd(dppf) Cl_2 (53 mg, 0.072 mmol) was added to a mixture of 1-(tert-butoxycarbonyl)-4-fluoro-1H-indol-2-ylboronic acid (200 mg, 0.717 mmol), 2,6-dichloropyrazine (106 mg, 0.717 mmol) and K_3PO_4 (572 mg, 2.151 mmol) in DMF (2 mL) under N_2 . The mixture was stirred at 80°C overnight under N_2 . The mixture was then diluted with water (40 mL) and extracted with EA (25 mL * 3). The organic layer was washed with brine (30 mL * 3), dried over Na_2SO_4 and concentrated. The residue was purified by prep-TLC (PE : EA = 8 : 1) to afford the desired product of tert-butyl 2-(6-chloropyrazin-2-yl)-4-fluoro-1H-indole-1-carboxylate (150 mg, yield: 60.2 %). $^1\text{H-NMR}$ (CDCl_3 , 400 MHz) δ 8.65 (s, 1H), 8.50 (s, 1H),


7.91 (d, $J = 8.4$ Hz, 1H), 7.24~7.30 (m, 1H), 6.88~6.94 (m, 2H), 1.35 (s, 9H). MS (M+H)⁺: 348 / 350.

Step 4 - Synthesis of 2-(6-chloropyrazin-2-yl)-4-fluoro-1H-indole




A mixture of tert-butyl 2-(6-chloropyrazin-2-yl)-4-fluoro-1H-indole-1-carboxylate (150 mg, 0.432 mmol) in HCl / CH₃OH (10 mL) was stirred at RT for 2 hours. The mixture was then concentrated to afford the product of 2-(6-chloropyrazin-2-yl)-4-fluoro-1H-indole (100 mg, yield: 93.4 %). ¹H-NMR (CDCl₃, 400 MHz) δ 9.33 (s, 1H), 8.92 (s, 1H), 8.37 (s, 1H), 7.13~7.17 (m, 3H), 6.73~6.78 (m, 1H). MS (M+H)⁺: 248 / 250.

Step 5 - Synthesis of 5-(6-(4-fluoro-1H-indol-2-yl)pyrazin-2-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide




Pd₂(dba)₃ (10 mg, 0.011 mmol) and X-Phos (10 mg, 0.022 mmol) were added to a mixture of 2-(6-chloropyrazin-2-yl)-4-fluoro-1H-indole (58 mg, 0.241 mmol), 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzofuran-3-carboxamide (121 mg, 0.241 mmol) and K₃PO₄ (175 mg, 0.657 mmol) in dioxane / H₂O (1.6 mL / 0.4 mL) under N₂. The mixture was stirred at 110°C overnight. The mixture was then diluted with water (3 mL) and extracted with EtOAc (20 mL * 3). The organic layer was washed with brine (30 mL * 3), dried over Na₂SO₄ and concentrated. The residue was purified by prep-TLC (PE : EA = 1 : 1.5) to afford the desired product of 5-(6-(4-fluoro-1H-indol-2-yl)pyrazin-2-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (80 mg, yield: 56.7 %). ¹H-NMR (DMSO-*d*₆, 400 MHz) δ 12.03 (s, 1H), 9.29 (s, 1H), 8.72 (s, 1H), 8.52 (d, $J = 4.4$ Hz, 1H), 8.16 (s, 1H), 7.98~8.03 (m, 3H), 7.38~7.46 (m, 3H), 7.32 (d, $J = 8.4$ Hz, 1H), 7.09~7.14 (m, 1H), 6.78~6.82 (m, 1H), 3.33 (s, 3H), 2.97 (s, 3H), 2.80 (d, $J = 5.2$ Hz, 3H). MS (M+H)⁺: 588.

Step 6 - Synthesis of 5-(6-(4-fluoro-1H-indol-2-yl)pyrazin-2-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide




A mixture of 5-(6-(4-fluoro-1H-indol-2-yl)pyrazin-2-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (30 mg, 0.051 mmol) and HCl / CH₃OH (20 mL) was concentrated in vacuum. The residue was then dissolved in CH₃OH (10 mL) and Pt/C (20 mg) was added to the solution. The mixture was stirred at 30°C under H₂ (35 Psi) for 24 hours. The mixture was then filtered through Celite. The filtrate was concentrated and purified by prep-HPLC to afford 5-(6-(4-fluoro-1H-indol-2-yl)piperazin-2-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido) benzofuran-3-carboxamide (15 mg, yield: 50.0 %). ¹H-NMR (Methanol-d₄, 400 MHz) δ 8.35 (d, *J* = 11.2 Hz, 1H), 7.94~7.98 (m, 3H), 7.28~7.32 (m, 2H), 7.21~7.24 (m, 1H), 7.07~7.13 (m, 1H), 6.66~6.75 (m, 2H), 5.07~5.16 (m, 1H), 4.67~4.81 (m, 1H), 3.70~3.89 (m, 2H), 3.52~3.60 (m, 2H), 3.57 (s, 3H), 3.14 (d, *J* = 18.0 Hz, 3H), 3.00 (s, 3H). MS (M+H)⁺: 594.

Examples 14 and 15: 5-(1-(4-fluoro-1-methyl-1H-indole-2-carbonyl)pyrrolidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)




Step 1 - Synthesis of tert-butyl 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate




To a solution of 5-bromo-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (100 mg, 0.22 mmol), tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (65 mg, 0.22 mmol) and K₂CO₃ (61 mg, 0.44 mmol) in 1,4-dioxane (5 mL) and H₂O (0.2 mL) was added Pd(dppf)Cl₂ (15 mg) under nitrogen. The reaction mixture was heated at 100°C for 2 h. The mixture was diluted with water and extracted with EtOAc. The combined organic phase was washed with brine, dried over Na₂SO₄ and concentrated. The residue was purified by prep-HPLC to afford the product of tert-butyl 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (80 mg, yield: 67%). ¹H-NMR (CDCl₃, 400 MHz) δ 7.85~7.92 (m, 2H), 7.75~7.79 (m, 1H), 7.52 (s, 1H), 7.15~7.19 (m, 2H), 6.05~6.18 (m, 1H), 5.75~5.80 (m, 1H), 4.50~4.54 (m, 2H), 4.29~4.33 (m, 2H), 3.25 (s, 3H), 3.00 (d, *J* = 4.0 Hz, 6H), 1.48 (s, 9H). MS (M+H)⁺: 544.

Step 2 - Synthesis of 5-(2,5-dihydro-1H-pyrrol-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide




To a solution of tert-butyl 3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (100 mg, 0.18 mmol) in DCM (5 mL) was added TFA (1 mL) under N₂ protection at 0°C. The mixture was stirred at room temperature for 2 h. After being concentrated, the residue was purified by prep-HPLC to give the product of 5-(2,5-dihydro-1H-pyrrol-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (50 mg, yield: 62%). ¹H-NMR (CDCl₃, 400 MHz) δ 7.87~7.92 (m, 2H), 7.76 (s, 1H), 7.51 (s, 1H), 7.18 (t, *J* = 8.4 Hz, 2H), 6.72 (s, 1H), 5.82 (brs, 1H), 4.17 (s, 2H), 3.96 (s, 2H), 3.25 (s, 3H), 2.98~3.00 (m, 6H). MS (M+H)⁺: 444.

Step 3 - Synthesis of 5-(1-(4-fluoro-1-methyl-1H-indole-2-carbonyl)-2,5-dihydro-1H-pyrrol-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide



To a solution of 5-(2,5-dihydro-1H-pyrrol-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (70 mg, 0.16 mmol), 4-fluoro-1-methyl-1H-indole-2-carboxylic acid (30.5 mg, 0.16 mmol) in THF (5 mL) was added Et₃N (48 mg, 0.47 mmol) and T₃P (152 mg, 0.24 mmol) at 0°C under nitrogen. After being stirred at 0°C for 30 minutes and RT overnight, the reaction mixture was quenched with H₂O, extracted with EA, dried over Na₂SO₄ and concentrated in vacuo. The crude product was purified by prep-HPLC to give 5-(1-(4-fluoro-1-methyl-1H-indole-2-carbonyl)-2,5-dihydro-1H-pyrrol-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (34 mg, yield: 35%). ¹H-NMR (CDCl₃, 400 MHz) δ 7.75~7.84 (m, 3H), 7.43~7.48 (m, 1H), 7.08~7.19 (m, 4H), 6.87~6.92 (m, 1H), 6.70~6.76 (m, 1H), 6.22~6.24 (m, 1H), 5.72~5.78 (m, 1H), 4.89 (brs, 2H), 4.63~4.68 (m, 2H), 3.93 (s, 3H), 3.22~3.27 (m, 3H), 2.90~2.97 (m, 6H). MS (M+H)⁺: 619.

Step 4 - Synthesis of (R) 5-(1-(4-fluoro-1-methyl-1H-indole-2-carbonyl)pyrrolidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide and (S) 5-(1-(4-fluoro-1-methyl-1H-indole-2-carbonyl)pyrrolidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide




To a degassed solution of 5-(1-(4-fluoro-1-methyl-1H-indole-2-carbonyl)-2,5-dihydro-1H-pyrrol-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (150 mg, 0.24 mmol) in EtOH (20 mL) was added Pd/C (30 mg) under N₂, then the mixture was stirred at RT under H₂ balloon for 10 hours. The reaction mixture was filtrated and the filtrate was concentrated. The residue was purified by SFC to give two single enantiomers.


Example 14 (enantiomer 1, peak 1 on SFC, OD-H_3UM_3_5_40_4ML_3MIN, HPLC_RT=1.879 min) (50 mg, yield: 34 %). ¹H-NMR (CDCl₃, 400 MHz) δ 7.98 (s, 1H), 7.82~7.88 (m, 2H), 7.42~7.46 (m, 1H), 7.15~7.23 (m, 4H), 6.75~6.89 (m, 2H), 5.80~5.82 (m, 1H), 3.81~4.15 (m, 9H), 3.33~3.37 (m, 2H), 2.96~3.05 (m, 6H), 2.46~2.71 (m, 2H). MS (M+H)⁺: 621.

Example 15 (enantiomer 2, peak 2 on SFC, OD-H_3UM_3_5_40_4ML_3MIN, HPLC_RT=2.164 min) (50 mg, yield: 34 %). ¹H-NMR (CDCl₃, 400 MHz) δ 7.98 (s, 1H), 7.82~7.88 (m, 2H), 7.42~7.46 (m, 1H), 7.15~7.23 (m, 4H), 6.75~6.89 (m, 2H), 5.80~5.82 (m, 1H), 3.81~4.15 (m, 9H), 3.33~3.37 (m, 2H), 2.96~3.05 (m, 6H), 2.46~2.71 (m, 2H). MS (M+H)⁺: 621.

Example 16: 5-(2-(4-fluoro-1H-indol-2-yl)-1-methylpiperidin-4-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide




Step 1 - Synthesis of 2-(4-fluoro-1H-indol-2-yl)-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)-1-methylpyridinium iodide



A mixture of 5-(2-(4-fluoro-1H-indol-2-yl)pyridin-4-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (100 mg, 0.17 mmol, prepared from 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzofuran-3-carboxamide according to previous patent) and CH₃I (50 mg, 0.35 mmol) in DMF (2 mL) was stirred at 80°C overnight. The mixture was


concentrated to afford a crude product of 2-(4-fluoro-1H-indol-2-yl)-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethanesulfonamido)benzofuran-5-yl)-1-methylpyridinium iodide (110 mg, yield: 89 %), which was used in the next step without further purification. ¹H-NMR (DMSO-*d*₆, 400 MHz) δ 12.47 (br s, 1H), 9.14 (d, *J* = 6.4 Hz, 1H), 8.55 (d, *J* = 4.0 Hz, 1H), 8.38 (s, 1H), 8.28 (s, 1H), 8.15 (d, *J* = 6.0 Hz, 1H), 7.91~7.98 (m, 3H), 7.39~7.48 (m, 4H), 7.26~7.35 (m, 1H), 6.95 (t, *J* = 9.2 Hz, 1H), 4.51 (s, 3H), 3.08 (br s, 3H), 2.87 (s, 3H), 2.82 (d, *J* = 4.0 Hz, 3H). MS (M+H)⁺: 601.

Step 2 - Synthesis of 5-(2-(4-fluoro-1H-indol-2-yl)-1-methylpiperidin-4-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide



A mixture of 2-(4-fluoro-1H-indol-2-yl)-4-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethanesulfonamido)benzofuran-5-yl)-1-methylpyridinium iodide (50 mg, 0.07 mmol) and PtO₂ (30 mg) in CH₃OH (10 mL) was stirred at 50°C for 2 days under H₂ (50 Psi). The mixture was filtered through Celite and concentrated, and the residue was purified by prep-TLC (DCM : MeOH = 10 : 1) to give 5-(2-(4-fluoro-1H-indol-2-yl)-1-methylpiperidin-4-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (20 mg, yield: 48 %). ¹H-NMR (MeOD, 400 MHz) δ 7.93 (dd, *J* = 7.6, 5.5 Hz, 2H), 7.77~7.86 (m, 2H), 7.22~7.32 (m, 3H), 7.10~7.18 (m, 1H), 6.84 (s, 1H), 6.70~6.79 (m, 1H), 4.50~4.68 (m, 1H), 3.76~3.93 (m, 2H), 3.41~3.56 (m, 1H), 3.35 (d, *J* = 17.6 Hz, 3H), 3.11 (d, *J* = 10.8 Hz, 3H), 3.00 (s, 3H), 2.74 (s, 3H), 2.12~2.70 (m, 4H). MS (M+H)⁺: 607.


Examples 17 and 18: 2-(4-fluorophenyl)-5-(1-(2-(4-fluorophenyl)acetyl)piperidin-3-yl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)



Synthesis of 2-(4-fluorophenyl)-5-(1-(2-(4-fluorophenyl)acetyl)piperidin-3-yl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)

A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (100 mg, 0.202 mmol), 4-fluorophenylacetic acid (62.2 mg, 0.403 mmol), DMAP (1.232 mg, 10.08 μ mol), N,N-diisopropylethylamine (130 mg, 1.008 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (62.6 mg, 0.403 mmol) in DCM (5 mL) was stirred at RT overnight under N₂ protection. The reaction mixture was concentrated and separated by SFC on a AD-H, 2x25 cm, 35% MeOH/CO₂ to afford Example 17 (Enantiomer 1, peak 1 on SFC, HPLC_RT=3.43 min) as white solid 30 mg (50%) (LC-MS (ES, m/z) C₃₁H₃₁F₂N₃O₅S: 595; Found: 596 [M+H]⁺) and Example 18 (Enantiomer 2, peak 2 on SFC, HPLC_RT=5.05 min) as white solid 33 mg (55%) (LC-MS (ES, m/z) C₃₁H₃₁F₂N₃O₅S: 595; Found: 596 [M+H]⁺).

Examples 19 and 20: 5-(1-(4-fluorobenzoyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)




Synthesis of 5-(1-(4-fluorobenzoyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (Enantiomer 1) and (S)-5-(1-(4-fluorobenzoyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (Enantiomer 2)

A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (100 mg, 0.202 mmol), 4-fluorobenzoic acid (56.5 mg, 0.403 mmol), DMAP (1.232 mg, 10.08 μ mol), N,N-diisopropylethylamine (130 mg, 1.008 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (62.6 mg, 0.403 mmol) in DCM (5 mL) was stirred at RT overnight under N₂ protection. The reaction mixture was concentrated and separated by SFC on a ChiralPak AS-H, 3x25 cm, 40% EtOH(0.1%NH₃.H₂O)/CO₂ to afford Example 19 (Enantiomer 1, peak 1 on SFC, HPLC_RT=2.26 min) as white solid 36 mg (59%) (LC-MS (ES, m/z) C₃₀H₂₉F₂N₃O₅S: 581; Found: 582 [M+H]⁺) and Example 20 (Enantiomer 2,

peak 2 on SFC, HPLC_RT=2.73 min) as white solid 38 mg (62.2%) (LC-MS (ES, m/z)
 $C_{30}H_{29}F_2N_3O_5S$: 581; Found: 582 $[M+H]^+$)


- 5 Example 21 and 22: 5-(1-(1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)



- 10 Synthesis of 5-(1-(1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)

- A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (100 mg, 0.202 mmol), 1H-indole-2-carboxylic acid (65 mg, 0.403 mmol), DMAP (1.232 mg, 10.08 μ mol), N,N-diisopropylethylamine (130 mg, 1.008 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (62.6 mg, 0.403 mmol) in
 15 DCM (5 mL) was stirred at RT overnight under N_2 protection. The reaction mixture was concentrated and separated by SFC on a ChiralPak AS-H, 3x25 cm, 40% MeOH(0.1% $NH_3 \cdot H_2O$)/ CO_2 to afford Example 21 (Enantiomer 1, peak 1 on SFC, HPLC_RT=4.15 min) as white solid 41 mg (67.3%) (LC-MS (ES, m/z) $C_{32}H_{31}FN_4O_5S$: 602;
 20 Found: 603 $[M+H]^+$) and Example 22 (Enantiomer 2, peak 2 on SFC, HPLC_RT=5.49 min) as white solid 38 mg (62.4%) (LC-MS (ES, m/z) $C_{32}H_{31}FN_4O_5S$: 602; Found: 603 $[M+H]^+$).


- Examples 23 and 24: 2-(4-fluorophenyl)-N-methyl-5-(1-(1-methyl-1H-benzo[d]imidazole-2-carbonyl)piperidin-3-yl)-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide
 25 (enantiomers 1 and 2)



Synthesis of 2-(4-fluorophenyl)-N-methyl-5-(1-(1-methyl-1H-benzo[d]imidazole-2-carbonyl)piperidin-3-yl)-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)

A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (80 mg, 0.161 mmol), 1-methyl-1H-benzo[d]imidazole-2-carboxylic acid (56.8 mg, 0.323 mmol), DMAP (0.985 mg, 8.06 μ mol), N,N-diisopropylethylamine (104 mg, 0.806 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (50.1 mg, 0.323 mmol) in DCM (5 mL) was stirred at RT overnight under N₂ protection. The reaction mixture was concentrated and separated by SFC on a ChiralPak AS-H, 4.6x25 cm, 5-40% MeOH(0.05%DEA)/CO₂ to afford Example 23 (Enantiomer 1, peak 1 on SFC, HPLC_RT=8.39 min) as white solid 65 mg (96%) (LC-MS (ES, m/z) C₃₃H₃₂F₂N₄O₅S: 634; Found: 635 [M+H]⁺) and Example 24 (Enantiomer 2, peak 2 on SFC, HPLC_RT=9.32 min) as white solid 60 mg (93.8%) (LC-MS (ES, m/z) C₃₃H₃₂F₂N₄O₅S: 634; Found: 635 [M+H]⁺).


Examples 25 and 26: 5-(1-(4-fluoro-1-methyl-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)



Synthesis of 5-(1-(4-fluoro-1-methyl-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (enantiomer 1) and 5-(1-(4-fluoro-1-methyl-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (enantiomer 2)

A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (100 mg, 0.202 mmol), 4-fluoro-1-methyl-1H-indole-2-carboxylic acid (67.8 mg, 0.403 mmol), DMAP (1.232 mg, 10.08 μ mol), N,N-diisopropylethylamine (130 mg, 1.008 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (62.6 mg, 0.403 mmol) in DCM (5 mL) was stirred at RT overnight under N₂ protection. The reaction mixture was concentrated and separated by SFC on a ChiralPak AS-H, 3x25 cm, 40% MeOH(0.1%NH₃.H₂O)/CO₂ to afford Example 25 (Enantiomer 1, peak 1 on SFC, HPLC_RT=4.15 min) as white solid 41 mg (67.3%) (LC-MS (ES, m/z) C₃₂H₃₁FN₄O₅S: 602; Found: 603 [M+H]⁺) and Example 26 (Enantiomer 2, peak 2 on SFC, HPLC_RT=5.49 min) as white solid 38 mg (62.4%) (LC-MS (ES, m/z) C₃₂H₃₁FN₄O₅S: 602; Found: 603 [M+H]⁺).

Examples 27 and 28: tert-butyl ((1R)-1-(2-fluorophenyl)-2-(3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)piperidin-1-yl)-2-oxoethyl)carbamate (diastereomers 1 and 2)




Synthesis of tert-butyl ((1R)-1-(2-fluorophenyl)-2-(3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)piperidin-1-yl)-2-oxoethyl)carbamate (diastereomers 1 and 2)

A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (110 mg, 0.222 mmol), (R)-2-((tert-butoxycarbonyl)amino)-2-(2-fluorophenyl)acetic acid (119 mg, 0.444 mmol), DMAP (1.355 mg, 0.011 mmol), N,N-diisopropylethylamine (143 mg, 1.109 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (68.9 mg, 0.444 mmol) in DCM (5 mL) was stirred at RT overnight under N₂ protection. The reaction mixture was concentrated and separated by SFC on a ChiralPak AS-H, 3x25 cm, 25% EtOH(0.1%NH₃.H₂O)/CO₂ to afford Example 27 (Diastereomer 1, peak 1 on SFC, HPLC_RT=7.16 min) as white solid 31.5 mg (40%) (LC-MS (ES, m/z) C₃₆H₄₀F₂N₄O₇S: 710; Found: 711 [M+H]⁺) and Example 28 (Diastereomer 2, peak 2 on

SFC, HPLC_RT=7.84 min) as white solid 47.2 mg (60%) (LC-MS (ES, m/z) C₃₆H₄₀F₂N₄O₇S: 710; Found: 711 [M+H]⁺)


Examples 29 and 30: 5-(1-((R)-2-amino-2-(2-fluorophenyl)acetyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (diastereomers 1 and 2)



10 Synthesis of 5-(1-((R)-2-amino-2-(2-fluorophenyl)acetyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (diastereomers 1 and 2)

A mixture of tert-butyl ((1R)-1-(2-fluorophenyl)-2-(3-(2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-(N-methylmethylsulfonamido)benzofuran-5-yl)piperidin-1-yl)-2-oxoethyl)carbamate (130 mg, 0.183 mmol), and hydrochloric acid (0.457 ml, 1.829 mmol) in 1,4-Dioxane (0.5 ml) was stirred at RT overnight under N₂ protection. The reaction mixture was concentrated and separated by SFC on a ChiralPak OD, 4.6x25 cm, 30% (3:1 MeOH/MeCN+0.2%DEA)/CO₂ to afford Example 29 (Diastereomer 1, peak 1 on SFC, HPLC_RT=3.99 min) as white solid 28 mg (56%) (LC-MS (ES, m/z) C₃₁H₃₂F₂N₄O₅S: 610; Found: 611 [M+H]⁺) and Example 30 (Diastereomer 2, peak 2 on SFC, HPLC_RT=4.64 min) as white solid 28 mg (56%) (LC-MS (ES, m/z) C₃₁H₃₂F₂N₄O₅S: 610; Found: 611 [M+H]⁺)


Example 31: (R)-5-(1-(7-fluoro-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide



Synthesis of (R)-5-(1-(7-fluoro-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide

To a solution of 7-fluoro-1H-indole-2-carboxylic acid (78 mg, 0.435 mmol), (R)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (100 mg, 0.218 mmol) in DCM (1 ml) was added N,N-diisopropylethylamine (169 mg, 1.306 mmol), and the reaction mixture stirred for 5 min at RT. Then 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (415 mg, 0.653 mmol) was added to the reaction mixture and stirred at RT overnight under N₂ protection. The reaction mixture was concentrated under vacuum, then applied onto a silica gel column and eluted with 0-30% MeOH/EtOAc. This resulted in 68 mg (50.3%) of (R)-5-(1-(7-fluoro-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide as white solid. LC-MS (ES, m/z) C₃₂H₃₀F₂N₄O₅S: 620; Found: 621 [M+H]⁺.

Example 32: (S)-5-(1-(7-fluoro-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide




32

Synthesis of (S)-5-(1-(7-fluoro-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide

To a solution of 7-fluoro-1H-indole-2-carboxylic acid (78 mg, 0.435 mmol), (S)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (100 mg, 0.218 mmol) in DCM (1 ml) was added N,N-diisopropylethylamine (169 mg, 1.306 mmol), and the reaction mixture stirred for 5 min at RT. Then 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (415 mg, 0.653 mmol) was added to the reaction mixture and stirred at RT overnight under N₂ protection. The reaction mixture was concentrated under vacuum, then applied onto a silica gel column and eluted with 0-30% MeOH/EtOAc. This resulted in 78 mg (58%) of (S)-5-(1-(7-fluoro-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-

fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide as white solid. LC-MS (ES, m/z) $C_{32}H_{30}F_2N_4O_5S$: 620; Found: 621 $[M+H]^+$.

Example 33: (S)-5-(1-(1-ethyl-4-fluoro-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide




33

10 Synthesis of (S)-5-(1-(1-ethyl-4-fluoro-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide

A mixture of (S)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (60 mg, 0.131 mmol), 1-ethyl-4-fluoro-1H-indole-2-carboxylic acid (54.1 mg, 0.261 mmol), DMAP (0.798 mg, 6.53 μ mol), N,N-diisopropylethylamine (84 mg, 0.653 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (40.5 mg, 0.261 mmol) in DCM (2 mL) was stirred at RT overnight under N_2 protection. The reaction mixture was concentrated under vacuum, then applied onto a silica gel column and eluted with 0-10% MeOH/EtOAc. This resulted in 46 mg (54.3%) of (S)-5-(1-(1-ethyl-4-fluoro-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide as white solid. LC-MS (ES, m/z) $C_{34}H_{34}F_2N_4O_5S$: 648; Found: 649 $[M+H]^+$.

Example 34: (R)-5-(1-(1-ethyl-4-fluoro-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide




25

34

Synthesis of (R)-5-(1-(1-ethyl-4-fluoro-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide

A mixture of (R)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (60 mg, 0.131 mmol), 1-ethyl-4-fluoro-1H-indole-2-carboxylic acid (54.1 mg, 0.261 mmol), DMAP (0.798 mg, 6.53 μ mol), N,N-diisopropylethylamine (84 mg, 0.653 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (40.5 mg, 0.261 mmol) in DCM (2 mL) was stirred at RT overnight under N₂ protection. The reaction mixture was concentrated under vacuum, then applied onto a silica gel column and eluted with 0-10% MeOH/EtOAc. This resulted in 38 mg (44.9%) of (R)-5-(1-(1-ethyl-4-fluoro-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide as white solid. LC-MS (ES, m/z) C₃₄H₃₄F₂N₄O₅S: 648; Found: 649 [M+H]⁺.

Example 35: (S)-5-(1-(1H-imidazo[4,5-b]pyridine-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide




35

Synthesis of (S)-5-(1-(1H-imidazo[4,5-b]pyridine-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide

A mixture of (S)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (70 mg, 0.152 mmol), 1H-imidazo[4,5-b]pyridine-2-carboxylic acid (49.7 mg, 0.305 mmol), DMAP (0.93 mg, 7.62 μ mol), N,N-diisopropylethylamine (98 mg, 0.762 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (47.3 mg, 0.305 mmol) in DCM (2 mL) was stirred at RT overnight under N₂ protection. The reaction mixture was concentrated under vacuum, then applied onto a silica gel column and eluted with 0-10% MeOH/EtOAc. This resulted in 45 mg (48.9%) of (S)-5-(1-(1H-imidazo[4,5-b]pyridine-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-

methylmethylsulfonamido)benzofuran-3-carboxamide as white solid. LC-MS (ES, m/z)
 $C_{30}H_{29}FN_6O_5S$: 604; Found: 605 $[M+H]^+$.

Example 36: (R)-5-(1-(1H-imidazo[4,5-b]pyridine-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide




36

Synthesis of (R)-5-(1-(1H-imidazo[4,5-b]pyridine-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide

A mixture of (R)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (70 mg, 0.152 mmol), 1H-imidazo[4,5-b]pyridine-2-carboxylic acid (49.7 mg, 0.305 mmol), DMAP (0.93 mg, 7.62 μ mol), N,N-diisopropylethylamine (98 mg, 0.762 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (47.3 mg, 0.305 mmol) in DCM (2 mL) was stirred at RT overnight under N_2 protection. The reaction mixture was concentrated under vacuum, then applied onto a silica gel column and eluted with 0-10% MeOH/EtOAc. This resulted in 58 mg (63%) of (R)-5-(1-(1H-imidazo[4,5-b]pyridine-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide as white solid. LC-MS (ES, m/z)
 $C_{30}H_{29}FN_6O_5S$: 604; Found: 605 $[M+H]^+$.

Example 37: Synthesis of (S)-5-(1-(7-fluoro-3-methyl-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide




37

Synthesis of (S)-5-(1-(7-fluoro-3-methyl-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide

A mixture of (S)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (75 mg, 0.163 mmol), 7-fluoro-3-methyl-1H-indole-2-carboxylic acid (63.1 mg, 0.326 mmol), DMAP (0.997 mg, 8.16 μ mol), N,N-diisopropylethylamine (105 mg, 0.816 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (50.7 mg, 0.326 mmol) in DCM (2 mL) was stirred at RT overnight under N₂ protection. The reaction mixture was concentrated under vacuum, then applied onto a silica gel column and eluted with 0-12% MeOH/EtOAc. This resulted in 58 mg (56%) of (S)-5-(1-(7-fluoro-3-methyl-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide as white solid. LC-MS (ES, m/z) C₃₃H₃₂F₂N₄O₅S: 634; Found: 635 [M+H]⁺.

Example 38: (R)-5-(1-(7-fluoro-3-methyl-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide




38

Synthesis of (R)-5-(1-(7-fluoro-3-methyl-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide

A mixture of (R)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (75 mg, 0.163 mmol), 7-fluoro-3-methyl-1H-indole-2-carboxylic acid (63.1 mg, 0.326 mmol), DMAP (0.997 mg, 8.16 μ mol), N,N-diisopropylethylamine (105 mg, 0.816 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (50.7 mg, 0.326 mmol) in DCM (2 mL) was stirred at RT overnight under N₂ protection. The reaction mixture was concentrated under vacuum, then applied onto a silica gel column and eluted with 0-12% MeOH/EtOAc. This resulted in 58 mg (56%) of (R)-5-(1-(7-

fluoro-3-methyl-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide as white solid. LC-MS (ES, m/z) $C_{33}H_{32}F_2N_4O_5S$: 634; Found: 635 $[M+H]^+$.

- 5 Example 39: (S)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(1-(7-(trifluoromethyl)-1H-indole-2-carbonyl)piperidin-3-yl)benzofuran-3-carboxamide



Synthesis of (S)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(1-(7-


- 10 *(trifluoromethyl)-1H-indole-2-carbonyl)piperidin-3-yl)benzofuran-3-carboxamide*

A mixture of (S)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (75 mg, 0.163 mmol), 7-(trifluoromethyl)-1H-indole-2-carboxylic acid (74.8 mg, 0.326 mmol), DMAP (0.997 mg, 8.16 μ mol), N,N-diisopropylethylamine (105 mg, 0.816 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (50.7 mg, 0.326 mmol) in DCM (2 mL) was stirred at RT overnight under N_2 protection. The reaction mixture was concentrated under vacuum, then applied onto a silica gel column and eluted with 0-100% EtOAc/Hexane. This resulted in 78 mg (71.3%) of (S)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(1-(7-(trifluoromethyl)-1H-indole-2-carbonyl)piperidin-3-yl)benzofuran-3-carboxamide as white solid. LC-MS (ES, m/z) $C_{33}H_{30}F_4N_4O_5S$: 670; Found: 671 $[M+H]^+$.

15

20

Example 40: (R)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(1-(7-(trifluoromethyl)-1H-indole-2-carbonyl)piperidin-3-yl)benzofuran-3-carboxamide




40

Synthesis of (R)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(1-(7-(trifluoromethyl)-1H-indole-2-carbonyl)piperidin-3-yl)benzofuran-3-carboxamide

A mixture of (R)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (75 mg, 0.163 mmol), 7-(trifluoromethyl)-1H-indole-2-carboxylic acid (74.8 mg, 0.326 mmol), DMAP (0.997 mg, 8.16 μ mol), N,N-diisopropylethylamine (105 mg, 0.816 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (50.7 mg, 0.326 mmol) in DCM (2 mL) was stirred at RT overnight under N₂ protection. The reaction mixture was concentrated under vacuum, then applied onto a silica gel column and eluted with 0-100% EtOAc/Hexane. This resulted in 88 mg (80%) of (R)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(1-(7-(trifluoromethyl)-1H-indole-2-carbonyl)piperidin-3-yl)benzofuran-3-carboxamide as white solid. LC-MS (ES, m/z) C₃₃H₃₀F₄N₄O₅S: 670; Found: 671[M+H]⁺.

Examples 41 and 42: 2-(4-fluorophenyl)-5-(1-(7-methoxy-1H-indole-2-carbonyl)piperidin-3-yl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)





Synthesis of (R)-2-(4-fluorophenyl)-5-(1-(7-methoxy-1H-indole-2-carbonyl)piperidin-3-yl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide and (S)-2-(4-fluorophenyl)-5-(1-(7-methoxy-1H-indole-2-carbonyl)piperidin-3-yl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide

A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (100 mg, 0.218 mmol), 7-methoxy-1H-indole-2-carboxylic acid (83 mg, 0.435 mmol), DMAP (1.329 mg, 10.88 μ mol), N,N-diisopropylethylamine (141 mg, 1.088 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (67.6 mg, 0.435 mmol) in DCM (5 mL) was stirred at RT overnight under N₂ protection. The reaction mixture was concentrated and separated by SFC on a ChiralPak AS-H, 3x25 cm, 40% MeOH (0.1% NH₃.H₂O) / CO₂ to afford Example 41 (Enantiomer 1, peak 1 on

SFC, HPLC_{RT}=3.52 min) as white solid 24 mg (35%) (LC-MS (ES, m/z) C₃₃H₃₃FN₄O₆S: 632; Found: 633 [M+H]⁺) and Example 42 (Enantiomer 2, peak 2 on SFC, HPLC_{RT}=6.21 min) as white solid 26 mg (37%) (LC-MS (ES, m/z) C₃₃H₃₃FN₄O₆S: 632; Found: 633 [M+H]⁺).



- 5 Examples 43 and 44: 2-(4-fluorophenyl)-N-methyl-5-(1-(1-methyl-1H-benzo[d]imidazol-2-yl)piperidin-3-yl)-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide



Synthesis of 2-(4-fluorophenyl)-N-methyl-5-(1-(1-methyl-1H-benzo[d]imidazol-2-yl)piperidin-3-yl)-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide

- 10 A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (80 mg, 0.174 mmol), 2-chloro-1-methyl-1H-benzo[d]imidazole (58 mg, 0.348 mmol) and triethylamine (106 mg, 1.045 mmol) in DMF (1 ml) was heated to 170°C for 10 min. The reaction mixture was cooled to RT and partitioned
- 15 between EtOAc and water, the organic layer dried in Na₂SO₄ and concentrated under vacuum. Then the reaction mixture separated by SFC on a ChiralCel OJ-H, 4.6x25 cm, 5-40% EtOH(0.05%DEA)/CO₂ to afford Example 43 (Enantiomer 1, peak 1 on SFC, HPLC_{RT}=8.28 min) as white solid 12.3 mg (24%) (LC-MS (ES, m/z) C₃₁H₃₂FN₅O₄S: 589; Found: 590 [M+H]⁺) and Example 44 (Enantiomer 2, peak 2 on SFC, HPLC_{RT}=9.13 min) as white solid 14.3 mg
- 20 (27%) (LC-MS (ES, m/z) C₃₁H₃₂FN₅O₄S: 589; Found: 590 [M+H]⁺).

Examples 45 and 46: 5-(1-(1H-benzo[d]imidazol-2-yl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)




25

Synthesis of 5-(1-(1H-benzo[d]imidazol-2-yl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)

A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (80 mg, 0.174 mmol), 2-chloro-1H-benzo[d]imidazole (34.5 mg, 0.226 mmol) and triethylamine (90 mg, 0.696 mmol) in DMF (1 ml) was heated to 170°C for 40 min. The reaction mixture was cooled to RT and partitioned between EtOAc and water, the organic layer dried in Na₂SO₄ and concentrated under vacuum. Then the reaction mixture separated by SFC on a ChiralCel OJ-3, 4.6x15 cm, 40% EtOH(0.05%DEA)/CO₂ to afford Example 45 (Enantiomer 1, peak 1 on SFC, HPLC_RT=1.89 min) as white solid 30 mg (60%) (LC-MS (ES, m/z) C₃₀H₃₀FN₅O₄S: 575; Found: 576 [M+H]⁺) and Example 46 (Enantiomer 2, peak 2 on SFC, HPLC_RT=2.68 min) as white solid 31 mg (62%) (LC-MS (ES, m/z) C₃₀H₃₀FN₅O₄S: 575; Found: 576 [M+H]⁺).


Examples 47 and 48: 5-(1-(benzo[d]oxazol-2-yl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)



Synthesis of 5-(1-(benzo[d]oxazol-2-yl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)

A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (80 mg, 0.174 mmol), 2-chlorobenzo[d]oxazole (34.8 mg, 0.226 mmol) and potassium carbonate (72.2 mg, 0.522 mmol) in DMF (1 ml) was heated to 60°C overnight under N₂ protection. The reaction mixture was cooled to RT and partitioned between EtOAc and water, the organic layer dried in Na₂SO₄ and concentrated under vacuum. Then the reaction mixture separated by SFC on a ChiralCel OJ-H, 4.6x25 cm, 5-40% EtOH (0.05%DEA) / CO₂ to afford Example 47 (Enantiomer 1, peak 1 on SFC, HPLC_RT=8.68 min) as white solid 38 mg (76%) (LC-MS (ES, m/z) C₃₀H₂₉FN₄O₅S: 576; Found: 577 [M+H]⁺) and Example 48 (Enantiomer 2, peak 2 on SFC, HPLC_RT=11.12 min) as white solid 30 mg (60%) (LC-MS (ES, m/z) C₃₀H₂₉FN₄O₅S: 576; Found: 577 [M+H]⁺).


Examples 49 and 50



5 Synthesis of 5-(1-(4-fluorobenzo[d]oxazol-2-yl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)

A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (80 mg, 0.174 mmol), 2-chloro-4-fluorobenzo[d]oxazole (38.8 mg, 0.226 mmol) and potassium carbonate (72.2 mg, 0.522 mmol) in DMF (1 ml) was heated to 60°C overnight under N₂ protection. The reaction mixture was cooled to RT and partitioned between EtOAc and water, the organic layer dried in Na₂SO₄ and concentrated under vacuum. Then the reaction mixture separated by SFC on a ChiralCel OJ-H, 4.6x25 cm, 35% EtOH (0.1%NH₃·H₂O) / CO₂ to afford Example 49 (Enantiomer 1, peak 1 on SFC, HPLC_RT=2.68 min) as white solid 42 mg (81%) (LC-MS (ES, m/z) C₃₀H₂₈F₂N₄O₅S: 594; Found: 595 [M+H]⁺) and Example 50 (Enantiomer 2, peak 2 on SFC, HPLC_RT=3.37 min) as white solid 38 mg (73%) (LC-MS (ES, m/z) C₃₀H₂₈F₂N₄O₅S: 594; Found: 595 [M+H]⁺).

Examples 51 and 52:




20 Synthesis of 5-(1-(5-fluorobenzo[d]oxazol-2-yl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (enantiomer 1) and (S)-5-(1-(5-fluorobenzo[d]oxazol-2-yl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (enantiomer 2)

25 A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (120 mg, 0.261 mmol), 2-chloro-5-fluorobenzo[d]oxazole (58.2 mg, 0.339 mmol) and potassium carbonate (108 mg, 0.783 mmol)

in DMF (1 ml) was heated to 60°C overnight under N₂ protection. The reaction mixture was cooled to RT and partitioned between EtOAc and water, the organic layer dried in Na₂SO₄ and concentrated under vacuum. Then the reaction mixture separated by SFC on a ChiralCel OJ-H, 3x25 cm, 45% EtOH(0.1%NH₃.H₂O)/CO₂ to afford Example 51 (Enantiomer 1, peak 1 on SFC, HPLC_RT=2.54 min) as white solid 23 mg (29.6%) (LC-MS (ES, m/z) C₃₀H₂₈F₂N₄O₅S: 594; Found: 595 [M+H]⁺) and Example 52 (Enantiomer 2, peak 2 on SFC, HPLC_RT=3.93 min) as white solid 31 mg (40%) (LC-MS (ES, m/z) C₃₀H₂₈F₂N₄O₅S: 594; Found: 595 [M+H]⁺).


Examples 53 and 54: 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)-5-(1-(oxazolo[4,5-b]pyridin-2-yl)piperidin-3-yl)benzofuran-3-carboxamide (enantiomers 1 and 2)



Synthesis of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)-5-(1-(oxazolo[4,5-b]pyridin-2-yl)piperidin-3-yl)benzofuran-3-carboxamide (enantiomers 1 and 2)

A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (120 mg, 0.261 mmol), 2-chlorooxazolo[4,5-b]pyridine (60.5 mg, 0.392 mmol) and potassium carbonate (108 mg, 0.783 mmol) in DMF (1 ml) was heated to 60°C overnight under N₂ protection. The reaction mixture was cooled to RT and partitioned between EtOAc and water, the organic layer dried in Na₂SO₄ and concentrated under vacuum. Then the reaction mixture separated by SFC on a ChiralCel OJ-H, 3x25 cm, 40% Isopropanol (0.1%NH₃.H₂O)/CO₂ to afford Example 53 (Enantiomer 1, peak 1 on SFC, HPLC_RT=3.37 min) as white solid 22 mg (29.3%) (LC-MS (ES, m/z) C₂₉H₂₈FN₅O₅S: 577; Found: 578 [M+H]⁺) and Example 54 (Enantiomer 2, peak 2 on SFC, HPLC_RT=4.19 min) as white solid 20 mg (26.7%) (LC-MS (ES, m/z) C₂₉H₂₈FN₅O₅S: 577; Found: 578 [M+H]⁺).

Examples 55 and 56: 5-(1-(4-fluoro-1H-benzo[d]imidazol-2-yl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)




Synthesis of 5-(1-(4-fluoro-1H-benzo[d]imidazol-2-yl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)

5 A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (80 mg, 0.174 mmol), 2-chloro-4-fluoro-1H-benzo[d]imidazole (47.5 mg, 0.279 mmol) and triethylamine (90 mg, 0.696 mmol) in DMF (1 ml) was heated to 170°C for 40 min. The reaction mixture was cooled to RT and partitioned between EtOAc and water. The organic layer was dried in Na₂SO₄ and concentrated under vacuum. Then the reaction mixture separated by SFC on a ChiralPark AD, 3x25 cm, 40% MeOH(0.1%NH₃.H₂O)/CO₂ to afford Example 55 (Enantiomer 1, peak 1 on SFC, HPLC_RT=3.91 min) as white solid 5 mg (10%) (LC-MS (ES, m/z) C₃₀H₂₉F₂N₅O₄S: 593; Found: 594 [M+H]⁺) and Example 56 (Enantiomer 2, peak 2 on SFC, HPLC_RT=6.34 min) as white solid 5 mg (10%) (LC-MS (ES, m/z) C₃₀H₂₉F₂N₅O₄S: 593; Found: 594 [M+H]⁺).

15

Examples 57 and 58: 2-(4-fluorophenyl)-5-(1-(5-(4-fluorophenyl)oxazol-2-yl)piperidin-3-yl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)



20 Synthesis of 2-(4-fluorophenyl)-5-(1-(5-(4-fluorophenyl)oxazol-2-yl)piperidin-3-yl)-N-methyl-6-(N-methylmethanesulfonamido)benzofuran-3-carboxamide (enantiomers 1 and 2)


A mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethanesulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (120 mg, 0.261 mmol), 2-chloro-5-(4-fluorophenyl)oxazole (61.9 mg, 0.313 mmol) and DIEA (67.5 mg, 0.522 mmol) in DMF (1 ml) was heated to 160°C for 30 min. The reaction mixture was cooled to RT and partitioned between EtOAc and water. The organic layer was dried in Na₂SO₄ and concentrated under

25

vacuum. Then the reaction mixture separated by SFC on a WHELK-O1(S,S), 3x25 cm, 50% MeOH (0.1%NH₃·H₂O)/CO₂ to afford Example 57 (Enantiomer 1, peak 1 on SFC, HPLC_RT=9.19 min) as white solid 33 mg (40.7%) (LC-MS (ES, m/z) C₃₂H₃₀F₂N₄O₅S: 620; Found: 621 [M+H]⁺) and Example 58 (Enantiomer 2, peak 2 on SFC, HPLC_RT=13.04 min) as
 5 white solid 30 mg (37%) (LC-MS (ES, m/z) C₃₂H₃₀F₂N₄O₅S: 620; Found: 621 [M+H]⁺).

Examples 59-78

These examples were synthesized using library format. To individual acid (0.078 mmol) in DMF (1 ml) was added DIEA (0.027 ml) then 0.266 ml T3P solution (50% in EtOAc).
 10 The solution was then treated with a 0.025 ml solution of amine (24 mg, from a solution of 576 mg amine 4 in 0.6 ml DMF). The solution was stirred at room temp for 16 h.



The reaction was filtered into a 96 well plate and submitted to high throughput
 15 purification.

Purification method for amides:

Column: Waters Sunfire C18, 5u, 19x100 mm

50 ml/min

8 minute run time

20 Mobile phase A = Water + .1% Formic Acid







Mobile phase B = MeCN + .1% Formic Acid







Gradient from 10 to 75% MeCN.

This work resulted in Examples 59 to 78.

<u>Ex.</u>	<u>Product Structure</u>	<u>IUPAC Name</u>	<u>Exact Mass</u> <u>[M+H]⁺</u>
------------	--------------------------	-------------------	---

59		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[1-(3-oxabicyclo[3.1.0]hex-6-ylcarbonyl)piperidin-3-yl]-1-benzofuran-3-carboxamide	570
60		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-{1-[(2-pyridin-2-ylcyclopropyl)carbonyl]piperidin-3-yl}-1-benzofuran-3-carboxamide	605
61		2-(4-fluorophenyl)-5-(1-{[2-(4-fluorophenyl)cyclopropyl]carbonyl}piperidin-3-yl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	622
62		5-{1-[(5-fluoro-3-methyl-1-benzofuran-2-yl)carbonyl]piperidin-3-yl}-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	636
63		2-(4-fluorophenyl)-N-methyl-5-[1-(3-methylbut-2-enoyl)piperidin-3-yl]-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	542

64		2-(4-fluorophenyl)-5-{1-[(4-methoxy-1H-indol-2-yl)carbonyl]piperidin-3-yl}-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	633
65		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[1-(1H-pyrrolo[3,2-b]pyridin-2-yl)carbonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	604
66		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[1-(1H-pyrrolo[2,3-b]pyridin-2-yl)carbonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	604
67		2-(4-fluorophenyl)-N-methyl-5-{1-[(1-methyl-1H-indol-2-yl)carbonyl]piperidin-3-yl}-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	617
68		5-[1-(cyclohexylacetyl)piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	584
69		5-[1-(1,3-benzothiazol-2-yl)carbonyl]piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	621


70		2-(4-fluorophenyl)-5-{1-[(5-fluoropyridin-2-yl)acetyl]piperidin-3-yl}-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	597
71		2-(4-fluorophenyl)-5-(1-{[4-(4-fluorophenyl)-1H-pyrrol-3-yl]carbonyl}piperidin-3-yl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	647
72		2-(4-fluorophenyl)-5-(1-{[2-(4-fluorophenyl)-1,3-oxazol-4-yl]carbonyl}piperidin-3-yl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	649
73		2-(4-fluorophenyl)-5-(1-{[3-(4-fluorophenyl)-1H-pyrazol-5-yl]carbonyl}piperidin-3-yl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	648
74		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-{1-[(4-methyl-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]piperidin-3-yl}-1-benzofuran-3-carboxamide	623
75		5-{1-[(6-fluoro-1,3-benzothiazol-2-yl)carbonyl]piperidin-3-yl}-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	639

76		5-{1-[(6-fluoro-1H-benzimidazol-2-yl)carbonyl]piperidin-3-yl}-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	622
77		5-[1-(1,3-benzoxazol-2-ylcarbonyl)piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	605
78		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-{1-[(2-pyridin-2-ylcyclopropyl)carbonyl]piperidin-3-yl}-1-benzofuran-3-carboxamide	605

Examples 79-84

These examples were synthesized using library format. To individual sulfonyl chlorides (0.109 mmol each) was added 1 ml MeCN solution of amine (25 mg) followed by

- 5 DIEA (0.047 ml). The reactions were shaken for 16 h. Then the reactions were filtered using a filter plate to a 96 well plate, which was sealed and submitted to High Throughput Purification.



10 Purification method:

Waters Sunfire C18, 5u, 19x100 mm

25 ml/min





10-12 minute run time

Mobile phase A = Water + .1% Formic Acid

Mobile phase B = MeCN + .1% Formic Acid

Gradient from 10 to 75% MeCN

This work resulted in Examples 79 to 84.






<u>Example</u>	<u>Product Structure</u>	<u>IUPAC Name</u>	<u>Mass</u> <u>[M+H]⁺</u>
79		2-(4-fluorophenyl)-N-methyl-6-[(methyl(methylsulfonyl)amino)-5-[(3R)-1-[(E)-2-phenylethenyl]sulfonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	626
80		5-[(3R)-1-[(4-fluorobenzyl)sulfonyl]piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[(methyl(methylsulfonyl)amino)-1-benzofuran-3-carboxamide	632
81		5-[(3R)-1-[(2-fluorobenzyl)sulfonyl]piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[(methyl(methylsulfonyl)amino)-1-benzofuran-3-carboxamide	632
82		5-[(3R)-1-[(3-fluorobenzyl)sulfonyl]piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[(methyl(methylsulfonyl)amino)-1-benzofuran-3-carboxamide	632







83		5-[(3R)-1-(1-benzofuran-2-ylsulfonyl)piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	640
84		5-{(3R)-1-[(3,4-difluorobenzyl)sulfonyl]piperidin-3-yl}-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	650

Examples 85-108






Examples 85 to 108 were prepared in library format. The procedure is exemplified by the synthesis of Example 85. To 5-fluoro-1-methyl-1*H*-indole-2-carboxylic acid (16 mg, was added a solution of (R)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (25mg, 0.054 mmol), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (34.9 mg, 0.109 mmol) and Hunig's base (14.1mg, 0.109 mmol) in 1 ml DMF. The mixture was stirred at room temperature for 18 h. The crude mixture was purified using mass directed reverse phase HPLC, Waters XBridge C18, 5u, 30 x 100 mm, 50 ml/min, 8 min run time, mobile phase A = water and ammonium, mobile phase B = acetonitrile and ammonium, gradient from 35% to 75% acetonitrile to give 5-{(3R)-1-[(5-fluoro-1-methyl-1*H*-indol-2-yl)carbonyl]piperidin-3-yl}-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide (25 mg, 71% yield). MS (M+H)⁺: 635.

Example	Structure	IUPAC Name	Mass [M+H] ⁺
85		5-{(3R)-1-[(5-fluoro-1-methyl-1 <i>H</i> -indol-2-yl)carbonyl]piperidin-3-yl}-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	635

86		5-[(3R)-1-[(5-fluoro-1,3-dimethyl-1H-indol-2-yl)carbonyl]piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	649
87		5-[(3R)-1-(1H-benzimidazol-2-yl)carbonyl]piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	604
88		5-[(3R)-1-[(4-fluoro-1H-indol-2-yl)carbonyl]piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	621
89		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3R)-1-{[1-methyl-5-(trifluoromethyl)-1H-indol-2-yl]carbonyl}piperidin-3-yl]-1-benzofuran-3-carboxamide	685
90		(R)-5-(1-(5-fluoro-1H-indole-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonylamido)benzofuran-3-carboxamide	621

91		(R)-5-(1-(7-fluorobenzofuran-2-carbonyl)piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonylamino)benzofuran-3-carboxamide	622
92		5-((3R)-1-[(6-fluoro-1H-benzimidazol-2-yl)carbonyl]piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	622
93		5-((3R)-1-[(6-fluoro-1,3-benzothiazol-2-yl)carbonyl]piperidin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	639
94		tert-butyl {(1S)-1-(2-fluorophenyl)-2-[(3R)-3-{2-(4-fluorophenyl)-3-(methylcarbamoyl)-6-[methyl(methylsulfonyl)amino]-1-benzofuran-5-yl}piperidin-1-yl]-2-oxoethyl}carbamate	711
95		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3R)-1-(quinoxalin-6-ylacetyl)piperidin-3-yl]-1-benzofuran-3-carboxamide	630
96		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3R)-1-[(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)carbonyl]piperidin-3-yl]-1-benzofuran-3-	646

97		carboxamide 2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3R)-1-[(4-oxo-3,4-dihydrophthalazin-1-yl)carbonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	632
98		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3R)-1-[morpholin-4-yl(phenyl)acetyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	663
99		5-[(3R)-1-[(6-bromo-1H-indazol-3-yl)carbonyl]piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	682
100		5-[(3R)-1-[(1-(cyclopropylmethyl)-1H-indazol-3-yl)carbonyl]piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	658
101		2-(4-fluorophenyl)-N-methyl-5-[(3R)-1-[(1-methyl-1H-indol-3-yl)carbonyl]piperidin-3-yl]-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	617

102		5-{{(3R)-1-[(6-fluoro-1H-indol-3-yl)carbonyl]piperidin-3-yl}-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	621
103		5-{{(3R)-1-[(5-bromoimidazo[1,2-a]pyridin-2-yl)carbonyl]piperidin-3-yl}-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	682
104		5-{{(3R)-1-[(8-amino-6-chloroimidazo[1,2-a]pyridin-2-yl)carbonyl]piperidin-3-yl}-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	653
105		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3R)-1-[(1,2,3-triazolo[1,5-a]pyridin-5-yl)carbonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	605
106		2-(4-fluorophenyl)-5-[(3R)-1-(indolizin-2-yl)carbonyl]piperidin-3-yl]-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	603

107		5-[(3R)-1-[(5-chloroimidazo[1,2-a]pyridin-2-yl)carbonyl]piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	638
108		5-[(3R)-1-(diphenylacetyl)piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	654

Examples 109 to 144

Examples 109 to 144 were prepared in library format. The procedure is exemplified by the synthesis of Example 111. To a solution of (S)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonylamido)-5-(piperidin-3-yl)benzofuran-3-carboxamide (20 mg, 0.044 mmol) and Hunig's base (11.3 mg, 0.087 mmol) in DCM was added 2-methylbenzene-1-sulfonyl chloride (17 mg, 0.089 mmol). The mixture was stirred uncapped for 18 hours. The crude mixture was purified using mass directed reverse phase HPLC, Waters Sunfire C18, 5u, 19 x 100 mm, 25 ml/min, 8 min run time, mobile phase A = water and 0.1% formic acid, mobile phase B = acetonitrile and 0.1% formic acid, gradient from 35% to 70% acetonitrile (14 mg, 51% yield) to afford 2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3S)-1-[(2-methylphenyl)sulfonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide. MS (M+H)⁺: 614.







<u>Example</u>	<u>Structure</u>	<u>IUPAC Name</u>	<u>Mass</u> <u>[M+H]⁺</u>
109		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3S)-1-[(2-methylphenyl)sulfonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	615






110		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3S)-1-[(pyridin-3-ylmethyl)sulfonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	615
111		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3S)-1-[(2-methylphenyl)sulfonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	614
112		5-[(3S)-1-[(1,3-benzothiazol-6-yl)sulfonyl]piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	657
113		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3S)-1-[(4-methylphenyl)sulfonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	614
114		2-(4-fluorophenyl)-5-[(3S)-1-[(3-fluorophenyl)sulfonyl]piperidin-3-yl]-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	618
115		2-(4-fluorophenyl)-5-[(3S)-1-[(4-fluorophenyl)sulfonyl]piperidin-3-yl]-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	618

116		5-[(3S)-1-(cyclohexylsulfonyl)piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	606
117		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3S)-1-(phenylsulfonyl)piperidin-3-yl]-1-benzofuran-3-carboxamide	600
118		5-{(3S)-1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]piperidin-3-yl}-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	680
119		2-(4-fluorophenyl)-5-{(3S)-1-[(2-fluorophenyl)sulfonyl]piperidin-3-yl}-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	618
120		5-[(3S)-1-(2,1,3-benzoxadiazol-4-ylsulfonyl)piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	642
121		5-[(3S)-1-(benzylsulfonyl)piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	614

122		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3S)-1-[(2-oxo-2,3-dihydro-1H-indol-5-yl)sulfonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	655
123		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3S)-1-[(pyridin-2-ylmethyl)sulfonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	615
124		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3S)-1-[(2-phenylethyl)sulfonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	628
125		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3S)-1-[(6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-3-yl)sulfonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	658
126		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3S)-1-[(3-methylphenyl)sulfonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	614
127		2-(4-fluorophenyl)-N-methyl-5-[(3S)-1-[(4-methyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)sulfonyl]piperidin-3-yl]-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-	672

		carboxamide	
128		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3R)-1-[(2-methylphenyl)sulfonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	614
129		5-[(3R)-1-(1,3-benzothiazol-6-yl)sulfonyl]piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	657
130		2-(4-fluorophenyl)-5-[(3R)-1-[(3-fluorophenyl)sulfonyl]piperidin-3-yl]-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	618
131		2-(4-fluorophenyl)-5-[(3R)-1-[(4-fluorophenyl)sulfonyl]piperidin-3-yl]-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	618
132		5-[(3R)-1-(cyclohexylsulfonyl)piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	606
133		5-[(3R)-1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	680

134		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3R)-1-(phenylsulfonyl)piperidin-3-yl]-1-benzofuran-3-carboxamide	600
135		5-[(3R)-1-(cyclopentylsulfonyl)piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	592
136		2-(4-fluorophenyl)-5-[(3R)-1-[(2-fluorophenyl)sulfonyl]piperidin-3-yl]-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	618
137		5-[(3R)-1-(benzylsulfonyl)piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	614
138		5-[(3R)-1-(2,1,3-benzoxadiazol-4-ylsulfonyl)piperidin-3-yl]-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	642
139		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3R)-1-[(pyridin-2-ylmethyl)sulfonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	615

140		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3R)-1-[(pyridin-3-ylmethyl)sulfonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	615
141		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3R)-1-[(2-phenylethyl)sulfonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	628
142		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3R)-1-[(3-methylphenyl)sulfonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	614
143		2-(4-fluorophenyl)-N-methyl-5-[(3R)-1-[(3-methyl-1-(2-methylpropyl)-1H-pyrazol-4-yl)sulfonyl]piperidin-3-yl]-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide	660
144		2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-5-[(3R)-1-[(pyridin-4-ylmethyl)sulfonyl]piperidin-3-yl]-1-benzofuran-3-carboxamide	615

Example 145: Measuring Compound Inhibitory Potency

Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or mutations were used.

In addition, potency measurements were made using different formats of the replicon assay, including different ways of measurements and different plating formats. *See Jan M. Vrolijk et al., A replicons-based bioassay for the measurement of interferons in patients with chronic hepatitis C*, 110 J. VIROLOGICAL METHODS 201 (2003); Steven S. Carroll *et al.*, *Inhibition of Hepatitis C Virus RNA Replication by 2'-Modified Nucleoside Analogs*, 278(14) J. BIOLOGICAL CHEMISTRY 11979 (2003). However, the underlying principles are common to all of these determinations, and are outlined below.

Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was determined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. *See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor*, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate format for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A. IC₅₀ determinations were calculated as a percentage of a DMSO control by fitting the data to a four-parameter fit function and the data obtained is provided in the table below.

Data for selected compounds of the present invention was obtained for genotypes 1a and 1b using this method and is provided in the table below:

Example#	1a IC ₅₀ (nM)	1b IC ₅₀ (nM)	Example #	1a IC ₅₀ (nM)	1b IC ₅₀ (nM)
1	56.91	34.3	73	50.5	23.36
2	84.07	41.04	74	54.75	43.37
3	148.2	109.4	75	72.29	12.02
4	7.026	6.525	76	49.36	9.961
5	53.68	19.34	77	64.3	19.24
6	11.12	17.37	78	248.2	81.15

7	5.79	11.59	79	64.78	33.12
8	28.22	36.89	80	3.165	4.5
9	53.98	67.85	81	14.13	11.63
10	16	26.58	82	2.203	3.262
11	21.36	17.23	83	38.22	22.45
12	92.81	37.76	84	2.774	3.035
13	140.5	165.2	85	25.99	12.49
14	25.87	2.768	86	233.7	115.2
15	125.4	11.25	87	267.1	111.6
16	332.6	106.4	88	70.72	38.69
17	137.7	58.2	89	84.36	45.18
18	187.8	72.25	90	41.59	20.72
19	43.76	50.83	91	180.1	62.56
20	48.04	46.9	92	274.2	96.96
21	16.22	9.96	93	180.7	102
22	40.84	18.77	94	299.9	167.6
23	45.47	57.71	95	175.8	105.9
24	32.68	40.46	96	423.3	218.6
25	16.43	5.259	97	335.6	470.3
26	15.79	12.59	98	240.6	111.8
27	44.41	35.21	99	136.8	66.74
28	23.86	21.39	100	65.04	20.39
29	83.13	147.8	101	103.2	55.87
30	122.3	215.1	102	345.3	295.2
31	17.08	9.38	103	212.5	109.9
32	53.12	19.18	104	283.8	136.4
33	129.8	196.5	105	347	219.4
34	84.09	65.3	106	122.9	51.5
35	71.59	48.93	107	388.8	116.5
36	269.4	285.6	108	265.7	52.97

37	162.4	92.77	109	103.6	26.16
38	277.4	115.5	110	163.7	38.38
39	268.3	36.44	111	68.1	17.23
40	141.8	27.63	112	24.98	6.785
41	30.67	13.47	113	64.62	21.92
42	105.6	23.94	114	34.19	8.202
43	41.23	92.96	115	36.61	7.995
44	70.97	82.36	116	194.5	31.67
45	224.6	70.9	117	32.34	9.373
46	11.94	9.474	118	41.04	8.357
47	8.368	5.372	119	24.53	10.92
48	40.19	24.75	120	22.44	8.37
49	5.764	7.439	121	47.54	23.82
50	81.65	20.06	122	78.77	22.15
51	4.99	7.118	123	105.5	29.77
52	32.64	42.64	124	182	72.92
53	14.57	15.7	125	172.5	67.61
54	7.383	13.87	126	46.86	13.17
55	5.652	3.626	127	90.19	32.35
56	53.66	23.85	128	34.24	24.2
57	19.88	22.2	129	193.7	109.6
58	132.5	36.15	130	174.1	95.47
59	307.6	119.7	131	175.6	88.94
60	115.9	40.31	132	93.34	56.11
61	251.4	99.55	133	105.8	74.65
62	192.1	41.18	134	85.9	58.31
63	156	68.11	135	80.38	45.63
64	135.2	40.72	136	58.48	40.45
65	140.1	46.26	137	2.15	3.04
66	92.59	21.21	138	139.2	55.67
67	156.2	87.42	139	35.04	21.07
68	97.95	88.95	140	20.46	16.51


69	74.44	22.76	141	10.61	14.23
70	206.8	67.94	142	198.2	91.72
71	168.3	95.43	143	314.7	213.6
72	124.9	23.62	144	36.17	28.56

It will be appreciated that various of the above-discussed and other features and functions, or alternatives thereof, may be desirably combined into many other different systems or applications. Also that various presently unforeseen or unanticipated alternatives,

5 modifications, variations or improvements therein may be subsequently made by those skilled in the art which are also intended to be encompassed by the following claims.

WHAT IS CLAIMED IS:

1. A compound having the formula:



- 5 or a pharmaceutically acceptable salt thereof,
wherein:

X is a 5 or 6-membered saturated monocyclic ring with 1 or 2 heteroatom ring atoms independently selected from N and O;

A is fluorophenyl;

- 10 B is
- a) hydrogen;
 - b) $-\text{C}(\text{O})\text{CH}=\text{C}(\text{CH}_3)_2$;
 - c) Ar;
 - d) $-\text{C}(\text{O})-\text{Ar}$;
 - e) $-\text{C}(\text{O})\text{CHR}^y-\text{Ar}$;
 - 15 f) $-\text{C}(\text{O})\text{CH}(\text{NHR}^x)-\text{Ar}$;
 - g) $-\text{SO}_2(\text{CH}_2)_{0-2}-\text{Ar}$;
 - h) $-\text{SO}_2-\text{CH}=\text{CH}-\text{Ar}$;
 - i) $-\text{CO}-\text{Cyc}$;
 - j) $-\text{COCH}_2-\text{Cyc}$;
 - 20 k) $-\text{SO}_2-\text{Cyc}$;

Ar is an aromatic ring system selected from:

- (i) 5-6 membered monocyclic ring with 0, 1, or 2 heteroatom ring atoms independently selected from N or O, optionally substituted with 1 or 2 substituents independently selected from fluorophenyl, $\text{C}_1\text{-C}_6$ alkyl, and halo; and
 - 25 (ii) 8-10 membered bicyclic rings with 1, 2 or 3 heteroatom ring atoms selected from N, O and S, optionally substituted with 1, 2 or 3 substituents independently selected from $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkoxy, halo, CF_3 , cyano, oxo, $-\text{NH}_2$, and cyclopropylmethyl;
- Cyc is $\text{C}_3\text{-C}_6$ cycloalkyl optionally substituted with fluorophenyl or pyridine; or

3-oxabicyclo[3.1.0]hexane;

D is H or $\text{NR}^3\text{SO}_2\text{R}^4$;


R^2 , R^3 , and R^4 are independently $\text{C}_1\text{-C}_6$ alkyl;

R^a is hydrogen or $\text{C}_1\text{-C}_6$ alkyl;

5 R^x is hydrogen or $\text{C}(\text{O})\text{OC}(\text{CH}_3)_3$; and

R^y is hydrogen, morpholinyl or Ar.

2. The compound of claim 1, wherein X is




3. The compound of claim 1 or 2, wherein R^2 , R^3 and R^4 are methyl.


4. The compound of any one of claims 1 to 3, wherein D is $\text{N}(\text{CH}_3)\text{SO}_2\text{CH}_3$.

5. The compound of any one of claims 1 to 4, wherein each halo is F.

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof,


20 having the formula:



7. The compound of any one of claims 1 to 6, wherein X is .

8. The compound of any one of claims 1 to 7, wherein B is Ar, $-\text{C}(\text{O})-\text{Ar}$, or $-\text{SO}_2-\text{Ar}$; wherein Ar is a 9-membered bicyclic ring with 1, 2, or 3 heteroatom ring atoms selected from N, O and S, optionally substituted with 1, 2 or 3 substituents independently selected from $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkoxy, F, CF_3 , and cyano.


9. The compound of claim 8, wherein Ar is





wherein each R^p is independently selected from hydrogen, methyl, methoxy, F, CF_3 , or cyano, and R^q is hydrogen, methyl or ethyl.


10. The compound of any one of claims 1 to 7, wherein B is $-\text{SO}_2-\text{Ar}$, $-\text{SO}_2\text{CH}_2-\text{Ar}$, $-\text{SO}_2\text{CH}_2\text{CH}_2-\text{Ar}$, $-\text{C}(\text{O})-\text{Ar}$; or $-\text{C}(\text{O})\text{CH}_2-\text{Ar}$; wherein Ar is phenyl, methylphenyl, fluorophenyl, difluorophenyl, pyridine, or fluoropyridine.


11. The compound of claim 1 which is any one of:






















5









5











or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 which is any one of





or a pharmaceutically acceptable salt thereof.

- 5 13. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an effective amount of the compound of any one of claims 1-12 or a pharmaceutically acceptable salt thereof.
- 10 14. The pharmaceutical composition of claim 13, further comprising a second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents.
- 15 15. The pharmaceutical composition of claim 14, wherein the second therapeutic agent is selected from the group consisting of HCV NS3 and NS3/4A protease inhibitors, HCV NS5A inhibitors and HCV NS5B polymerase inhibitors.
- 20 16. A use of the compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for inhibiting HCV NS5B activity or for preventing and/or treating infection by HCV in a patient in need thereof.
17. A compound according to any one of claims 1 to 12 for use in treating a patient infected with HCV.

18. A method of treating a patient infected with HCV, the method comprising administering to the patient the compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, in an amount effective to prevent and/or treat infection by HCV in the patient.

5

19. The method of claim 18, further comprising administering to said patient an effective amount of at least one second therapeutic agent selected from the group consisting of HCV NS3 and NS3/4A protease inhibitors, HCV NS5A inhibitors and HCV NS5B polymerase inhibitors.

10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2014/043075

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 31/343 (2014.01)

CPC - A61K 31/343 (2014.10)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - A61K 31/343; C07D 405/04 (2014.01)

CPC - A61K 31/343, 45/06 (2014.10) (keyword delimited)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
USPC - 514/337, 469; 549/468 (keyword delimited)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatBase, STN, Google Patents, Google Scholar, PubChem

Search terms used: benzofuran hepatitis fluorophenyl

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2004/0162318 A1 (SAHA et al) 19 August 2004 (19.08.2004) entire document	1-3
A	US 2004/0132720 A1 (MARSHALL et al) 08 July 2004 (08.07.2004) entire document	1-3
A	US 2012/0328569 A1 (MCCOMAS et al) 27 December 2012 (27.12.2012) entire document	1-3

☐

Further documents are listed in the continuation of Box C.

☐

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21 November 2014

Date of mailing of the international search report

10 DEC 2014

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Blaine R. Copenheaver

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2014/043075

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 4, 5, 7-10, 13-19
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Claims 1-3 have been analyzed subject to the restriction that the claims read on the Formula (I) as described in the Lack of Unity of Invention (See Extra Sheet). The claims are restricted to a compound having Formula (I); or a pharmaceutically acceptable salt thereof, wherein: X is a 5 membered saturated monocyclic ring with 1 heteroatom ring atom selected from N; A is fluorophenyl; B is hydrogen; D is H; R₂ is C₁-C₆ alkyl; and Ra is hydrogen.

<See Extra Sheet>

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-3

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2014/043075

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees need to be paid.

Group I+: Claims 1-3, 6, 11, and 12 are drawn to a compound having Formula (I) or a pharmaceutically acceptable salt thereof.

The first invention of Group I+ is restricted to a compound having Formula (I); or a pharmaceutically acceptable salt thereof, wherein: X is a 5 membered saturated monocyclic ring with 1 heteroatom ring atom selected from N; A is fluorophenyl; B is hydrogen; D is H; R2 is C1-C6 alkyl; and Ra is hydrogen. It is believed that claims 1-3 read on this first named invention and thus these claims will be searched without fee to the extent that they read on the above embodiment.

Applicant is invited to elect additional formula(e) for each additional compound to be searched in a specific combination by paying an additional fee for each set of election. An exemplary election would be a compound having Formula (I); or a pharmaceutically acceptable salt thereof, wherein: X is a 6 membered saturated monocyclic ring with 1 heteroatom ring atom selected from N; A is fluorophenyl; B is hydrogen; D is H; R2 is C1-C6 alkyl; and Ra is hydrogen. Additional formula(e) will be searched upon the payment of additional fees. Applicants must specify the claims that read on any additional elected inventions. Applicants must further indicate, if applicable, the claims which read on the first named invention if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched/examined.

The inventions listed in Groups I+ do not relate to a single general inventive concept under PCT Rule 13.1, because under PCT Rule 13.2 they lack the same or corresponding special technical features for the following reasons:

The Groups I+ formulae do not share a significant structural element, requiring the selection of alternatives for the compound variables X, A, B, D, R2, R3, R4, Ra, Rx, and Ry.

The Groups I+ share the technical features of a compound having a core structure of Formula (I); or a pharmaceutically acceptable salt thereof. However, these shared technical features do not represent a contribution over the prior art.

Specifically, US 2004/0162318 A1 to Saha et al. teach a compound having a core structure of Formula (I); or a pharmaceutically acceptable salt thereof (See Pg. 81, Table 1-continued, Example number 426, 2-(4-Fluoro-phenyl)-5-furan-2-yl-6-methanesulfonylamino-benzofuran-3-carboxylic acid methylamide).

The inventions listed in Groups I+ therefore lack unity under Rule 13 because they do not share a same or corresponding special technical feature.